Review

Current Strategies to Enhance Delivery of Drugs across the Blood–Brain Barrier

Raluca Ioana Teleanu 1,2, Manuela Daniela Preda 3, Adelina-Gabriela Niculescu 3,*, Oana Vladâcenco 1,2, Crina Ioana Radu 4, Alexandru Mihai Grumezescu 3,5,6,7* and Daniel Mihai Teleanu 2

1 Department of Pediatric Neurology, “Dr. Victor Gomoiu” Children’s Hospital, 022102 Bucharest, Romania; raluca.teleanu@umfcd.ro (R.I.T.); oana-aurelia.vladacenco@drd.umfcd.ro (O.V.)
2 “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania; daniel.teleanu@umfcd.ro
3 Department of Science and Engineering of Oxide Materials and Nanomaterials, Faculty of Applied Chemistry and Materials Science, Politehnica University of Bucharest, 011061 Bucharest, Romania; manuela.preda@stud.fim.upb.ro (M.D.P.); adelina.niculescu@upb.ro (A.-G.N.)
4 Department of Neurosurgery (I), Bucharest University Emergency Hospital, 050098 Bucharest, Romania; crina.radu95@gmail.com
5 Research Institute of the University of Bucharest—ICUB, University of Bucharest, 050657 Bucharest, Romania
6 Academy of Romanian Scientists, Ilfov No. 3, 050044 Bucharest, Romania
7* Correspondence: grumezescu@yahoo.com

Abstract: The blood–brain barrier (BBB) has shown to be a significant obstacle to brain medication delivery. The BBB in a healthy brain is a diffusion barrier that prevents most substances from passing from the blood to the brain; only tiny molecules can pass across the BBB. The BBB is disturbed in specific pathological illnesses such as stroke, diabetes, seizures, multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease. The goal of this study is to offer a general overview of current brain medication delivery techniques and associated topics from the last five years. It is anticipated that this review will stimulate readers to look into new ways to deliver medications to the brain. Following an introduction of the construction and function of the BBB in both healthy and pathological conditions, this review revisits certain contested questions, such as whether nanoparticles may cross the BBB on their own and if medications are selectively delivered to the brain by deliberately targeted nanoparticles. Current non-nanoparticle options are also discussed, including drug delivery via the permeable BBB under pathological circumstances and the use of non-invasive approaches to improve brain medication absorption.

Keywords: blood–brain barrier; medication delivery techniques; nanoparticles

1. Introduction

Brain diseases, such as central nervous system (CNS) disorders and brain cancers, are the most common, debilitating, and underserved diseases [1]. As the population of seniors and patients with CNS disorders grows over the next 20 years, global drug development for brain diseases must accelerate. However, drug development for brain diseases has the lowest success rates compared to other therapeutic areas. CNS drugs typically take much longer to develop than non-CNS drugs. Because of the complexity of the brain, side effects, and the blood–brain barrier, clinical trials of CNS drugs are difficult [2].

Aside from the complexity of brain diseases, the lack of efficient technologies for delivering drugs across the BBB stymies CNS drug development. Small molecules and macromolecules are being studied as potential therapeutic agents for various brain diseases [3].

However, only small molecules with a molecular weight up to 400 Da and that are lipid-soluble can cross the BBB; most macromolecules cannot penetrate the brain endothelium [4]. The BBB’s physiological barrier prevents 95% of molecules from progressing toward drug development [5]. Recent research has shown that the BBB is a dynamic interface that...
regulates access of substances from the blood into the brain [4,5]. These advances highlight the importance of rethinking some concepts about brain drug delivery while also revealing significant opportunities for new drug delivery strategies.

This review discusses recent advances in our understanding of the BBB and its disruption in disease conditions. It focuses on new strategies that have been investigated in the last five years to deliver therapeutic and diagnostic agents to the brain. In addition, the effect of aging on the BBB is analyzed.

2. General Background on the Blood–Brain Barrier

The brain barrier is significant to medication delivery to the central nervous system. They are made up of numerous parallel barriers; the two best characterized being the vascular BBB, which is made up mostly of the capillary bed, and the blood-cerebrospinal fluid (blood-CSF) barrier, which is made up primarily of the choroid plexus [6,7].

All tissues and organs in the body rely on blood arteries to provide oxygen and nutrients [7,8]. The blood–brain barrier (BBB) is a set of features that allow the blood vessels that vascularize the CNS to strictly regulate the transit of ions, chemicals, and cells between the blood and the brain [9]. Changes in these barrier properties are a significant component of the pathophysiology and development of numerous neurological illnesses since they allow for optimal neuronal activity while also shielding neural tissue from poisons and pathogens [10].

Endothelial cells (ECs), which constitute the walls of blood arteries, veins, and capillaries of the brain, skin, lung, heart, and muscle, have a number of physical, transport, and metabolic features that help to coordinate the physiological barrier. Interactions with diverse vascular, immunological, and brain cells influence these features [11]. Understanding how these various cell types interact to modify barrier properties is crucial to understanding how the brain functions in health and disease.

The blood–brain barrier is a part of the neurovascular unit (NVU) that acts as a blood–brain interface, allowing the CNS to communicate with the rest of the body. The BBB divides the circulatory system from the brain, providing for serum factor and neurotoxic protection as well as transport management. In addition to acting as a physical barrier (due to the presence of specialized tight junctions and other changes that prevent unregulated leakage), the BBB serves as a transport interface (with specific transporters present on luminal and abluminal membranes), a secretory body, and a metabolic barrier (containing and releasing certain enzymes locally) [12].

The loss of these barrier qualities during neurological illnesses such as stroke, multiple sclerosis (MS), brain traumas, and neurodegenerative disorders is a fundamental component of their pathophysiology and development [13]. BBB disruption can result in ion dysregulation, disrupted signaling homeostasis, and immune cell and molecule entrance into the CNS, all of which can contribute to neuronal dysfunction and degeneration [12]. Figure 1 presents the blood–brain barrier elements.
2.1. The Blood–Brain Barrier in a Healthy Brain

The BBB is a diffusion barrier necessary for regular brain function that prevents chemicals from entering the blood and reaching the brain, thus maintaining brain homeostasis. Endothelial cells, pericytes, astrocytes, tight junctions (TJs), neurons, and the basal membrane of the brain form physically tight brain capillaries in the BBB [15]. The absence of fenestrations in brain capillary ECs inhibits the transport of tiny molecules and proteins. Interendothelial junctions connect the ECs to a continuous barrier, preventing water-soluble compounds from penetrating. Pericytes, astrocytes, and the basal membrane surround the ECs, forming the BBB.

Furthermore, efflux transporters are found in brain capillary ECs, which are additional barriers to drugs entering the brain. Interendothelial junctions and protein complexes such as adherens junctions, TJs, and gap junctions primarily govern BBB permeability [16]. Adherens junctions are principally responsible for regulating the permeability of the endothelial barrier. TJs are necessary for the epithelium and ECs to maintain their permeability barriers, which govern tissue homeostasis [17]. Gap junctions, which are made up of six connexin molecules, allow ECs to communicate directly in both electric and chemical terms. The components of the BBB are continually adjusting in response to different physiological changes in the brain, rather than having a set structure [16].

Molecules can pass the BBB through either a paracellular (between neighboring cells) or a transcellular route (through the cells). Ions and solutes use concentration gradients to move across the BBB via passive diffusion in the paracellular route. Passive diffusion, receptor-mediated transport, and transcytosis are part of the transcellular route. In general, passive diffusion is a non-saturable process determined by the molecule’s physicochemical features. Molecular weight, charge, lipid solubility, surface activity, and relative molecule size are all physicochemical parameters that impact BBB permeability [18].

Small lipophilic molecules such as carbon dioxide diffuse passively over the BBB via a transcellular pathway. BBB permeability can be influenced by physiological factors such as efflux transporters (e.g., P-glycoprotein (P-gp)), enzymatic activity, plasma protein
binding, and cerebral blood flow [19]. Glucose transporter-1 (GLUT-1), insulin transporter, and transferrin transporter are examples of distinct and highly value receptor-mediated transport routes that allow proteins and peptides to reach the brain [20]. The luminal and abluminal EC membranes exhibit these endogenous transporters. Among these transport systems, receptor-mediated transcytosis has received the most attention in drug delivery into the brain [21]. Greater knowledge of the mechanics of passage over the BBB will aid in the development of innovative medication delivery techniques into the brain.

2.2. Blood–Brain Barrier Disruption in Certain Pathological Conditions

Stroke, diabetes, seizures, hypertensive encephalopathy, acquired immunodeficiency syndrome, traumatic brain traumas, multiple sclerosis, Parkinson’s disease (PD), and Alzheimer’s disease (AD) (Figure 2) all disrupt the BBB [22–24]. Remodeling the protein complex at interendothelial junctions is a significant cause of BBB collapse in some clinical circumstances.

Figure 2. Schematic illustration summarizing some of the major neurological disorders associated with impairment of the BBB. Reprinted from Ref. [25], MDPI, 2021.

Shiraishi et al. evaluated magnetic resonance imaging (MRI) contrast agents, gadolinium micelles (Gd-micelles), and gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) in rats after intravenous administration. They found a greater contrast signal from Gd-micelles in the ischemic hemisphere than from Gd-DTPA, demonstrating a hyperpermeable BBB under ischemia circumstances [26]. Remodeling the protein complex at interendothelial junctions is a significant cause of BBB collapse in some clinical circumstances. During an ischemic stroke, for example, the BBB becomes more permeable to macromolecules. Because albumin, a large protein molecule, seldom crosses the healthy BBB, it evaluates BBB leakage. In an R6/2 mouse model of Huntington’s disease, albumin-fluorescein isothiocyanate conjugate (FITC-albumin) was found in the brain at early and late disease stages, confirming BBB breakdown under these conditions [27].

The loss of junctional molecules in cholesterol-rich cell membrane areas contributes to increased BBB permeability in multiple sclerosis. Furthermore, altering adherens junctions can drastically alter BBB permeability [28]. As a result, it has been established that
connections are disturbed, and as a result, the BBB becomes permeable in some disorders. However, because of several constraints, the degree and time duration of BBB breakdown in each illness is unknown. Multiple sclerosis, for example, is characterized by a transitory or persistent decrease of BBB permeability. Although BBB breakdown may be seen in vivo by injecting a Gd contrast agent, MRI scanning may underestimate the total level of BBB disruption. BBB disruption, on the other hand, is linked to illness consequences. In the case of Alzheimer’s disease, vascular dementia and the disease are usually co-occurring. Along with many contradictory results, it is generally acknowledged that the increase in BBB permeability in certain Alzheimer’s patients is caused by vascular dementia, but not by pure Alzheimer’s disease [29]. Considering the intricacy of mechanisms in CNS illnesses, investigations on BBB disruption in diverse diseases are still in their early stages.

2.3. Blood–Brain Tumor Barrier

The most frequent type of primary brain tumor is glioma [30]. Brain tumor cells mirror the BBB in their early stages due to their rapid proliferation and movement. The BBB is disrupted when tumor cells reach a specific threshold. As a result, the blood–brain tumor barrier (BBTB) is separate from the BBB and is produced by new blood vessels (brain tumor capillary) (Figure 3). In glioblastomas, BBTB permeability is high in the bulk of the tumor but low or non-existent in the periphery [31].

As a result, the combination of the BBB and the BBTB creates a significant barrier to brain tumor medication delivery. To circumvent the BBB, strategies such as opening TJs using a hyperosmotic mannitol solution or a chemical (e.g., bradykinin), blocking efflux drug transporters, and receptor-mediated drug delivery systems may be used to improve medication delivery to brain tumors selectively. In addition to passing the BBTB, glioma cells must be targeted. Coating cell-permeable peptides might accomplish this on the surface of nanoparticles. A comprehensive review of peptides for glioma cell targeting may be obtained [33]. This review is mostly concerned with crossing the BBTB.

![Figure 3. Schematic representation of cerebral capillary showing endothelial cell in (A) normal and (B) glioblastoma. Reprinted with permission from Ref. [32], Copyright 2020, Elsevier.](image-url)
2.4. Approaches to Inhibit ABC Transporters

ATP-binding cassette (ABC) transporters are highly expressed by brain endothelial cells forming the BBB, being involved in maintaining brain homeostasis. Their enhanced activity represents a major obstacle in treating brain diseases, as ABC transporters impede drugs to reach their site of action within CNS [34]. Thus, a discussion on BBB would not be complete without properly addressing the topic of ABC transporters, especially considering the approaches to inhibit these efflux pumps.

Numerous transporter proteins in the ABC superfamily are involved in expelling compounds utilizing the catalytic energy of ATP. This superfamily actively effluxes substances in humans, as it does in other eukaryotic systems, extruding poisons and medications out of cells [35]. They work with a wide range of substrates, including tiny molecules like ions and molecules, as well as larger, highly organized structures like peptides, lipids, and polysaccharides [36]. In humans, 48 ABC transporters are categorized into seven subfamilies based on their genetic and amino acid structure, from A to G. Furthermore, ABC transporters are thought to hinder pharmacological substances from penetrating into the brain, posing a barrier to therapeutic delivery in neurological illnesses [37].

ABC transporters, which are significant players in the multidrug-resistant phenotype of glioma and other malignancies, efflux several chemotherapeutics [38]. As a result, many efforts have been made to improve tumor drug delivery by using competitive or non-competitive inhibitors, and many P-gp and BCRP inhibitors, such as valspodar [39], dexverapamil [40], tariquidar [41], biricodar [40], and elacridar, have been clinically evaluated for use as adjuvants on chemotherapy to treat non-brain tumors, as well as indirect inhibition by anti-P-gp monoclonal antibodies. Their effectiveness in overcoming the BBB has been tested in both animals and humans. In a rat xenograft model of glioma, for example, greater brain accumulation of erlotinib was reported when it was coadministered with elacridar [42].

The penetration of $^{11}$C-verapamil was increased when it was given with cyclosporine A in a clinical research on healthy volunteers [43]. However, due to adverse effects such as cardiovascular toxicity of first-generation inhibitors and pharmacokinetic interactions with chemotherapeutics (e.g., inhibition of CYPs450) leading to increased systemic cytotoxicity, ABC transporter inhibition has not been translated into clinical application. Furthermore, several modulators block more than one ABC transporter, such as elacridar and tariquidar, which inhibit both P-gp and BCRP, causing severe side effects such as hazardous chemical buildup in the brain, kidneys, liver, and other organs [44].

LY335979, formerly Zosuquidar trihydrochlorid, was designed as a strong and specific inhibitor of P-gp and was the most advanced compound being tested in the clinics [45]. Nagaya et al. employed zosuquidar in their most recent work to illustrate the influence of P-Glycoprotein–mediated active efflux on drug distribution.

Because the expression levels of P-gp in the BBB of cynomolgus monkeys are similar to those in humans, they were utilized. The effect of a P-gp inhibitor (zosuquidar) on drug CNS penetration in monkeys was also investigated in vivo to determine the influence of P-gp on drug CNS penetration. This work designed a zosuquidar dosing strategy to induce strong P-gp suppression throughout a 24-h period. The findings help them better understand how drugs penetrate the central nervous system in the preclinical stage [46].

But though inhibiting ABC transporters has still not been shown to be effective in clinical drug delivery, they have been a valuable resource in furthering our understanding of ABC transporter function and multidrug resistance in cancer, glioma, and other CNS pathologies, as well as their implications at the blood–brain interface [38].

3. Advances in Drug Delivery across the Blood–Brain Barrier

These strategic treatment techniques for circumventing the BBB can be roughly grouped into one or more of the following groups: invasive and non-invasive procedures, as well as other ways. The advantages and limitations of these two procedures are presented in Table 1.
### Table 1. Strategies for brain drug delivery.

| Type of Procedures                     | Strategies                                      | Advantages                                                                 | Limitations                                                                 | References |
|----------------------------------------|-------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|------------|
| **Invasive approaches**                |                                                 |                                                                            |                                                                            |            |
| Blood–brain barrier transient disruption| Transient opening; can achieve therapeutic concentrations | Non-targeted, entire BBB is disrupted                                       | [47,48]                                                                 |            |
| Intracerebroventricular and intrathecal infusion | High gene transfection efficiency                  | Safety concerns; direct brain injection; crossing the BBB; high dose by intravenous administration | [47,49,50] |            |
| Chemical modification of drugs         | Option for personalized medicine                 | Difficult to achieve therapeutic concentration in vivo; expensive and difficult to develop; non-targeted | [48]                                                                      |            |
| Virus-mediated blood–brain barrier delivery | High gene transfection efficiency                  | Safety concerns; direct brain injection; crossing the BBB; high dose by intravenous administration | [47,49,50] |            |
| Exosome-mediated blood–brain barrier delivery | Gene delivery to the brain; potential ability to cross the BBB | Exosome donor cells; loading procedure; in-vivo toxicity and pharmacokinetics | [47]                                                                      |            |
| Intranasal route of delivery           | Bypass the BBB through nasal administration       | Suitable for low dose                                                      |                                                                            | [51]       |
| Modulating blood–brain barrier permeability | Transiently open the BBB                           | Mismatch between findings in rodents and humans                            |                                                                            | [52,53]    |
| Focused ultrasound for brain diseases  | Therapeutic concentrations; targeted to sub-millimeter regions in the brain | Only relatively short-term studies have been performed                     |                                                                            | [48]       |
| Nanoparticles for brain imaging/diagnostics | Enhance imaging; cross the BBB through the hyper-permeable BBB under disease conditions | Cross the BBB; understand dynamic changes in the BBB                       |                                                                            | [22]       |
| Liposome-based strategies              | Exhibit strong biocompatibility and biodegradability; minimal toxicity; drug-targeted delivery; controlled drug release | Liposomes are not currently used in clinical practice to deliver brain-specific drugs |                                                                            | [54]       |
| Solid-lipid nanoparticles              | Site-specific targeted delivery (via receptor-mediated transcytosis across brain capillary endothelial cells); physical stability; ability to escape the reticulo-endothelial system; extended blood circulation time; sustained release; nontoxic; biodegradable; biocompatible | Smaller drug payload; a complicated physical state of the lipid content; storage and administration stability issues |                                                                            | [55]       |

### 3.1. Invasive Approaches

#### 3.1.1. Blood–Brain Barrier Transient Disruption

The use of noxious agents, hyperosmotic solutions, or ultrasounds (mannitol [56], dimethyl sulphoxide [57], ethanol [58], metals [59], glycerol [60], polysorbate-80 [61], X-irradiation [62]) to diminish the brain’s endothelial cells by breaking down tight con-
nections permits diverse substances to circulate into the cerebral tissue. Admittedly, this technique has significant drawbacks: it is not patient-friendly, and it may compromise the integrity and neurobiological functioning of the BBB, potentially resulting in the accumulation of unwanted blood components and neurotoxic, xenobiotic, and exogenous substances, which can cause CNS injury [63].

Electroporation is a recently proposed approach for producing transitory, localized BBB rupture (EP) [64]. During EP, pulsed electrical fields (PEFs) are administered to cells or tissue, causing the electrical potential across the cell membrane to destabilize. Changes in membrane potential cause the formation of nanoscale aqueous holes in the lipid bilayer, increasing the permeability of the cell membrane. If the membrane re-seals, this is referred to as reversible EP; if the PEFs cause cell death, this is referred to as irreversible EP [65]. Earlier studies established the possibility of obtaining EP-induced transitory BBB breakdown in rats after EP treatments using contrast-enhanced T1-weighted MRI [66]. These findings were confirmed in canines, and the electric field threshold for EP-induced BBB breakdown was determined to be in the 500–700 V/cm range in these investigations [67,68]. Bonakdar et al. and Lopez-Quintero et al. revealed that 750,000 low voltage (1–10 V) pulses (90 s pulses at 0.4 ms pulse intervals for 5 min) increased the permeability of bovine aortic endothelial cells in vitro [68]. They discovered higher hydraulic conductivity, which they ascribed to the ZO-1 protein’s disturbing continuity.

3.1.2. Intracerebroventricular and Intrathecal Infusion

These methods include injecting or infusing therapeutic proteins directly into the cerebrospinal fluid via intraventricular infusion (CSF) [69].

The advantages of these approaches over systemic enzyme replacement therapy (ERT) are that they allow for the transport of a greater number of enzymes to the brain and, as a result, do not require the use of enormous quantities of therapeutic medications. Furthermore, these solutions address the issues associated with the short half-life of medicines in circulation while avoiding those associated with systemic exposure and toxicity. A lumbar puncture or an implanted intrathecal medication delivery device can be used to provide intrathecal drugs (IDDD) [70].

ERT administered via intrathecal injection can allocate the recombinant enzyme all across the CNS, allowing it to penetrate brain tissue and start promoting the clearance of aggregated material within the lysosomes, according to statistics from animal models of MPS I, II, and IIIA, as well as other LSDs such as infantile neuronal ceroid lipofuscinosisis and Niemann-Pick A [71,72]. In recent years, researchers have concentrated their attention on creating and testing therapeutics for activation of the brain in MPS IIIA, due to the availability of mice [73] and dog models [74] capable of recapitulating the MPS IIIA neuropathological characteristics.

Clinical trials in humans have begun to test the safety and tolerability of recombinant human heparan-N-sulfatase (rhHNS) administered via IDDD in patients with MPS IIIA, pursuing the remarkable results of animal studies that showed that repetitive direct infusion of an absent enzyme via cerebrospinal fluid injection is a successful therapy for pathological changes in the brains of mice and dogs (NCT01155778 and NCT01299727) [22,54]. Similarly, the toxicity of idursulphase, which was formulated for intrathecal injection (idursulphase-IT) on MPS II patients, was investigated via IDDD [75]. Although the findings of these studies motivate more research, clinical implementation of these procedures is regarded as difficult due to the enzymes’ short half-life. Repeated doses with an increased risk of adverse consequences are required to improve effectiveness and raise the possibility of clinical success.

3.2. Non-Invasive Approaches

Non-invasive approaches mostly consist of pharmacological tactics capable of altering pharmaceuticals to allow them to pass across the BBB. The primary non-invasive procedures are detailed further below.
3.2.1. Chemical Modification of Drugs

The transvascular approach preceding systemic injection is the primary limitation but the only one to consider for chronic CNS disorders, whether tumoral or neurological [76]. Because many severe neurological disorders do not react to small-molecule treatments, large molecules, therapeutic peptides, inhibitors, or other medications are necessary [77]. As a result, medication delivery to the brain requires methods such as nanoparticles capable of ferrying pharmaceuticals over the BBB. The BBB excludes hydrophilic medications and the vast majority of molecules, although some (but not all) tiny (300 Da) lipophilic molecules may get through via diffusion [78,79]. A medicine can be lipidded to be carried to the brain, however, this strategy has had limited success since increasing lipophilicity may be efficient [80], but it usually comes at the expense of a greater biodistribution. As most transporters are selective, this technique requires that the medication imitate the endogenous ligand.

Following the Maillard process, glycosylation or glycation may improve medication and peptide transport to the brain while enhancing biological stability [81]. Due to better transport, which was likely controlled by adsorptive endocytosis instead of the glucose transporter, and retained bioactivity, Enkephalin-Ser6 b–DGlucose demonstrated higher blood stability and absorption by the brain [82]. EGF (a ligand for differentially expressed EGF receptors in brain cancer) or BDNF (a neurotrophic component) have been linked to a monoclonal antibody against transferrin receptor, resulting in bifunctional molecules that can attach to the BBB transferrin receptor, ferry peptides throughout the vascular wall, and distribute these peptides to the brain [62,63]. The activation of enzyme activities is also important in the BBB, and these functions can be changed by sickness. Aminopeptidase A activity is increased in brain tumors, but aminopeptidase N activity is reduced [83]. These differences are crucial for transporting undamaged molecules to the brain, and enzymatically intact (pro)drugs may be necessary, such as via cyclization, halogenation, methylation, pegylation, or the inclusion of unnatural bonds [84].

3.2.2. Virus-Mediated Distribution across the Blood–Brain Barrier

A viral vector can be delivered via the BBB using one of two methods. The first is transcytosis across brain vascular endothelial cells mediated by receptors [85]; the other is the BBB’s temporary disintegration [86], enabling the vector to reach CNS interstitial regions via paracellular transport.

Traditionally, this has been accomplished by osmotically decreasing the BBB cells via intravenous (IV) infusion of highly concentrated mannitol (25%). This sugar ethanol does not pass through the cell and is excreted through the kidneys fairly quickly. For decades, this technique has been used to facilitate the flow of chemotherapeutic drugs through the BBB to target brain cancers and to reduce intracranial pressure after traumatic brain injury or encephalitis [68,69].

Despite the fact that alternative ways for increasing BBB permeability exist, including adenosine receptor activation and human serum albumin nanoparticles, they still have not yet been employed to distribute viral vectors [70,71].

BBB osmotic rupture regulation controlled by mannitol has been utilized to transfer adenovirus (Ad), herpesvirus, adeno-associated virus (AAV), and SV40 to the CNS [87–89]. In an adult mouse model of mucopolysaccharidosis type IIIB, this method of treating neurodegenerative illness was shown to be therapeutically helpful (MPS IIIB) [90]. The syndrome is characterized by substantial CNS neurodegeneration owing to lysosome accumulation of heparan sulfate and its derivatives, which is caused by N-acetylglucosaminidase (NAGLU) alterations. However, MPS IIIB has major somatic symptoms such as hepatosplenomegaly and skeletal abnormalities; once enough vector can penetrate the CNS and lysosomal storage in the peripheral nervous system, it is a suitable candidate for systemic gene transfer [91]. AAV serotype 2 (AAV2), which does not normally traverse the BBB, and mannitol pretreatment were used to deliver the faulty NAGLU gene intravenously. While the number of brain cells transduced was small (about 1–2%), the
homogenous dispersion throughout the brain parenchyma, along with the cross-correction effects of the secreted NAGLU enzyme, allowed for extensive CNS disease correction. The timing of IV vector delivery in connection to mannitol administration was critical, with 8 min after pre-treatment generating 10-fold greater transduction than 5 or 10 min [90].

A highly concentrated and targeted vector transduction pathway can be achieved by transiently rupturing the BBB using magnetic-resonance-guided focused ultrasound plus IV-administered microbubbles, followed by IV-administered AAV vector [79]. This BBB permeabilization technique was created to treat a wide range of illnesses, and it depends on the mechanical action of lipid/gas microbubbles in reaction to ultrasonic pressure pulses to damage the brain endothelium for 6 h [92].

The new work recommends that the whole brain be permeabilized for gene therapy in a variety of disorders. Following IV treatment and FUS sonication in a grid scan method, a self-complementary AAV9-CMV-GFP vector rapidly and efficiently penetrated the whole brain of mice. When compared to non-FUS-GFP-injected mice, nearly the entirety of extracts of FUS-treated GFP-injected mice exhibited a rise in vector DNA (19.8 times), GFP mRNA (16.4 times), and GFP protein levels (17.4 times). There had been a 7.3-fold increase in infected cells in the cortex, hippocampus, and striatum, in case of an increase in GFP levels. In the brains of rats treated, no harmful consequences were seen. The use of FUS and AAV-based gene transfer to treat neurological genetic diseases is a significant step forward [93].

Despite paracellular transport over a compromised BBB showing promise in animal models, the alternative method of crossing the BBB through receptor-mediated transcytosis has recently shown greater promise. These methods are divided into three categories: employing a viral vector that naturally crosses the BBB (usually, AAV9 [94]); altering vectors to attach to a particular transcellular transport receptor; and changing vectors to attach to a specific transcellular transport receptor [95]. Guided evolution was used to generate a vector that binds with an appropriate receptor despite specifying which one. To carry huge molecules across the BBB, they all require highly specialized channels, typically targeting well-studied transporters like the transferrin receptor, LDL receptor-related proteins (LRP-1 and LRP-2), or insulin receptor [96].

3.2.3. Exosome-Mediated Transport across the Blood–Brain Barrier

Exosomes are naturally occurring vesicles found in virtually every human body cell. As a result, there has been considerable progress in understanding exosomes, including their function, processes, and compositions, over the last two decades. Extracellular vesicles, as endogenous NPs with the capability to bridge BBs, are being hailed as possible forerunners of a new era in medicine, with a variety of applications including prevention, intervention, and pharmacological and gene therapies [97]. As more information becomes available, it will be possible to alter EVs to become specific medication delivery systems (DDSs). The administration methods, payload, structure, selectivity, and reception for bridging BBs, on the other hand, are unclear and require further research [98].

To that purpose, various nano- and micro-sized structures, such as EVs [99], are classified according to their cellular origin, dimensions, biogenesis, and physicochemical features [100]. According to popular scientific assumptions, EVs are formed via the plasma membrane and endosomal processes. Exosomes, as previously said, are regarded as one of the most significant types of EVs, having an endosomal origin and a diameter of 50–100 nm [101] in cellular homeostasis, intracellular interaction, and molecular pathways that are engaged in physiological and pathological functions [102]. Donor cells can affect specific signaling pathways in recipient cells by transferring cytoplasmic proteins and lipids, as well as genetic components like iRNA, which are involved in diverse signal transduction pathways [103].

The key location in the BBB that governs exosomal transport is the EC. When circulatory exosomes come into physical contact with BBB ECs, various general processes involved in EV absorption, including the speeding-up of the influx of exosomes from the blood
into the brain tissue, endocytosis, micropinocytosis, phagocytosis, and plasma membrane fusion are used [104].

Exosomes are recognized to have the ability to cross the BBB under normal circumstances. It should not be overlooked that the development of inflammatory circumstances might disrupt the BBB, resulting in increased exosome transfer and permeability. A problem that supports this notion is the rapid movement of exosomes from the CSF to the bloodstream following the onset of CNS inflammatory alterations [105].

Because of broad capillary networks and specific subsets of immune cells with phagocytic receptors, a considerable percentage of systemically injected exosomes is soon caught in the hepatic, lung, and splenic tissues, according to several studies [74]. Through several investigations, unaltered exosomes may easily disseminate in biofluids via free dispersion without targeting capabilities [106]. As a result, surface modification tactics can be used to alter exosome targeting capabilities [107]. Conjugation of specific ligands to the surface of transplanted exosomes may improve the interaction with specific moieties on cells, while adding labeled radioactive, fluorescent, and MRI agents at the same time is a useful approach to track in vivo. In line with these descriptions, surface modification has been proposed as a potential method for increasing exosome trafficking via the BBB [108].

Exosome delivery has been accomplished via a variety of modification ways so far. Surface treatment using aptamers, non-covalent and covalent alterations, multivalent electrostatic interactions, and genetic engineering have all been utilized to alter the exosomal surface [109].

Exosome surfaces are functionalized with tiny and large biomolecules and polymers in click chemistry, for example, without altering exosome activity [108]. Chemical alteration is a more appealing modality due to its simplicity of synthesis, high throughput, and the large number of chemical reactions accessible [108,110,111]. The use of hazardous solvents like dimethyl sulfoxide, temperature and pressure fluctuations, and osmotic changes that might harm exosome structure are all inevitable drawbacks of traditional chemistries [109].

The use of a natural receptor on the luminal surface is a sensible alternative for increasing exosome transcytosis rates. LDLRs are membrane-bound receptors with a wide range of actions based on this. Endothelial endocytosis is mediated by these receptors, which have the potential to connect to a variety of ligands in addition to lipoprotein metabolism [110]. Exosomes containing KLA suppressed the development of human tumoroid U87 cells in vitro and increased extravasation via the BBB, leading to longer median survival rates than exosomes without KLA [112]. According to single-cell investigations, LDLR subsets also contribute to the route of endocytic cargo to the lysosomes. However, there is no clear evidence that LDLRs are involved in endocytosis or transcytosis [113]. Some data suggest that the LDLR2 subgroup, specifically, is involved in transcytosis [114]. According to these assertions, the formation of KLA-loaded exosomes should prioritize the activity of LDLR subsets that facilitate endothelial transcytosis over intracellular metabolism and protease activity. Otherwise, biotherapeutic compounds would be eliminated at the BBB level before reaching their target location.

Exosomes might be thought of as clever carriers for medication delivery to the brain parenchyma, according to earlier research and the mechanisms discussed in this article. Researchers may be able to improve the exosome–ECs interaction on the surface of the BBB and facilitate exosome passage, thereby increasing the efficacy of drug delivery to the abluminal side of the BBB, if they have a better understanding of the recruited mechanisms of exosomes passing through BBB and related challenges.

3.2.4. Intranasal Route of Delivery

Intranasal (IN) injection of medicines to the central nervous system has a number of advantages in the treatment of neurologic diseases. The blood–brain barrier restricts the use of most therapeutic drugs designed to treat memory loss and neurodegeneration because it restricts CNS penetration, based on drug size or charge [115]. Although invasive delivery techniques (such as intracerebroventricular) were used to circumvent the BBB,
these procedures are not feasible for use in humans due to a variety of factors, comprising accessibility, safety, and cost. IN administration crosses the BBB and offers a non-invasive approach to invasive medication administration by providing medications directly into the CNS from the nasal cavity. Many CNS medications, even those that may cross the BBB when taken systemically, benefit from non-invasive IN administration because it targets therapy to the CNS, reducing systemic exposure and side effects. IN delivery does not necessitate changes to CNS treatments, and therapeutic delivery to the CNS is quick, taking only minutes [116]. Frey invented the IN delivery technique in 1989 [117] to transfer neurotrophic factors to the CNS (such as nerve growth factor [NGF] and fibroblast growth factor-2).

Therapeutics delivered intranasally enter the CNS through the olfactory and trigeminal neuronal pathways. The nasal cavity is innervated by both the olfactory and trigeminal nerves, directly linking to the CNS. The olfactory pathway was once thought to be responsible for direct medicinal delivery from the nose to the brain [117,118]. The trigeminal pathway’s role in IN distribution to the CNS, particularly to caudal brain areas and the spinal cord, has recently been acknowledged [119,120].

IN delivery of neurotrophins appears to be a non-invasive strategy to direct neurotrophins to the CNS to treat neurodegeneration, according to growing data. IN given NGF decreased neurodegeneration and enhanced cognitive function in a mouse model of Alzheimer’s disease [121,122]. IN IGF-I decreased brain damage and neurologic impairments in a rat stroke model [123]. In addition, after IN injection of FGF-2 to adult mice, brain neurogenesis was promoted in the subventricular zone. In animal models of Alzheimer’s disease, neurodegeneration, tau pathologies, amyloid accumulation, and loss of memory have all been shown to be reduced by IN-activity-based neurotrophic factor and its functional peptide fragment NAP [124]. IN NAP is currently being investigated in phase II clinical studies as a potential Alzheimer’s disease and mild mental impairment treatment.

IN delivery is a non-invasive technique of delivering medications to the CNS, bypassing the BBB, and limiting systemic exposure and negative effects. This innovative approach has previously been shown to boost memory in healthy persons and Alzheimer’s disease sufferers. IN delivery has the potential to change the way Alzheimer’s disease and other neurodegenerative illnesses are treated.

3.2.5. Modulating Blood–Brain Barrier Permeability

There are four different types of adenosine receptors. A2A and A2B activate adenylate cyclase by binding to the Gs protein, whereas A1 and A3 decrease adenylate cyclase activity by binding to the Gi/o proteins [125]. The subunit determines the affinity of A2A receptors for Gs proteins; the greatest contact occurs with G proteins that include the four subunits. Stimulation of the receptors leads to a rise in cAMP amount in the cell. The expression of the A2A receptor is regulated by protein kinase C, which is altered in pathological circumstances. Using radiographic approaches, A2A receptors were discovered on leukocytes (e.g., neutrophils), platelets, blood vessels, and even inside the CNS, such as in the striatum [126]. Adenosine, as well as inosine and other exogenous compounds utilized in treatment, activate these receptors [127,128]. The expression of proteins that regulate BBB function may be changed in diseased situations. In the context of hypoxia or inflammation, substances like interleukin- or tumor-necrosis factor boost the expression of the A2A receptor in glial cells [129].

The activation of A2A receptors reduces platelet aggregation and controls blood pressure by vasodilation, according to Ledent et al. A2AR agonists influence pain pathways [130]. A2A receptor agonists have been shown to have a vasodilating impact in the coronary arteries of rats and the mesentery of dogs. Gong Zhao et al. discovered that the CVT-3146 adenosine receptor agonist’s vascular resistance-lowering impact was dosagedependent and had a more powerful effect on coronary arteries than adenosine [131].
Another essential role of A2A receptor agonists is to prevent tissue from injury during ischemia-reperfusion, such as in hemorrhagic shock, by lowering inflammation (affecting neutrophils, platelets, macrophages, and T cells) [132,133]. Furthermore, adenosine agonists in the central nervous system (CNS) reduce inflammation and protect nerve cells [134].

3.2.6. Focused Ultrasound for Brain Diseases

In recent years, ultrasound has become a popular method for allowing medications to pass across the BBB. MEUS, or microbubble-enhanced diagnostic ultrasonography, is a non-invasive approach that helps medications pass the BBTB by enhancing BBTB permeability in glioma patients. Major proteins in TJs in the BBB include claudins, occludin, and JAMs [135]. Ultrasound irradiation and microbubbles might suppress the expression of these TJ proteins [135], opening the BBB over a short period of time without causing injury to normal brain tissue [136]. Furthermore, MEUS increased the expression of KCa channels in glioma cells, according to Ningaraj et al., promoting pinocytosis and, as a result, increasing BBTB permeability. The BBB, in addition to the BBTB, is still a barrier to medication delivery in brain tumors. When focused ultrasound (FUS) is paired with microbubbles, the permeability of the BBTB in brain tumors can be increased while the BBB in the adjacent tissue is disrupted [137].

Park et al. exploited DCE-MRI to investigate the administration of doxorubicin using a combination of FUS and microbubbles. To transport doxorubicin to a rat brain cancer and the normal brain, researchers used FUS and microbubbles. They showed that using both techniques boosted drug retention duration in the tissue over 24 h while also improving drug crossing of the BBB and BBTB. Furthermore, MEUS’ ability to temporally decrease P-gp expression is intriguing. P-gp was suppressed for up to 48 h and then recovered after 72 h using MEUS, and the amount of induced suppression could be varied by changing instrument parameters. Non-human primates were given FUS at various sonic pressures to study the physiological changes in the brain caused by the BBB opening caused by FUS [138] (Figure 4).

In addition, Dallan McMahon et al. noted in their clinical study that, following FUS+MB exposure, DEX treatment was observed to speed up the repair of BBB integrity in the targeted dorsal hippocampus while also preventing an increase in the generation of inflammatory markers. These findings imply that DEX might be used to control the amount
to which BBB permeability is enhanced, allowing for repeated FUS+MB exposures with a lower risk of tissue harm caused by cumulative negative effects. The outcomes reported here indicate that DEX administration following FUS+MB exposure may be warranted in clinical cases where vascular damage is suspected and the goal of treatment is to restore or preserve neural function, based on its widespread clinical use and well-documented mechanisms of action [139].

The pharmacokinetic research indicated that FUS opened the BBB locally and transiently, facilitating medication transport. The amount of BBB opening, and hence the drug concentration in the brain, was influenced by brain inhomogeneity and acoustic pressure. The fundamental concepts of ultrasound-mediated medication administration may be discovered, as well as a full description of the possibilities [140]. In addition to FUS, medication distribution across the BBB was aided by transcranial magnetic stimulation (TMS), which promotes neuronal activity and boosts glutamate release [141]. TMS improved BBB permeability in 10 of 15 patients with malignant brain tumors in preliminary clinical research, showing that TMS might be used in clinical settings to improve medication delivery into the brain [142].

Roland Beisteiner et al. describes a clinical sonication approach based on single ultrashort ultrasound pulses (transcranial pulse stimulation, TPS). A first clinical trial employing ultrasonic brain stimulation is also described, as well as the first findings of long-term effects. Large safety margins and dose-dependent neuromodulation are seen in preclinical data. Patient examinations suggest that the medication is well-tolerated and that there are no serious adverse effects. TPS therapy improves neuropsychological scores dramatically, with improvements lasting up to three months and correlating with an upregulation of the memory network (fMRI data). The findings support a broad neuroscientific use of the approach, as well as its translation into therapeutic treatment and randomized sham-controlled clinical trials [143].

There are several potential advantages of concentrated US (quality of life, lifespan, lower expenses, shorter treatment duration), but are there any disadvantages? Therapy for massive brain tumors, for example, may take a long period, but there is now no other treatment option [144].

3.2.7. Nanoparticles for Brain Imaging/Diagnostics

The use of nanoparticles in tumor imaging and diagnosis has received much attention. However, due to the challenges posed by the BBB, little research has been conducted on brain imaging for CNS illnesses. The advancement of imaging technology, particularly MRI and computed tomography (CT), has revolutionized neurodegenerative disease care and prognosis. BBB disruption may be measured quantitatively in ischemic stroke patients using DCE-MRI [145]. The dynamic course of the damage and BBB breakdown following intracerebral hemorrhage, which is a substantial source of morbidity and mortality, has also been tracked using multimodal MRI [146]. Quantitative and visual measurement of increasing BBB permeability may assist in identifying suitable treatment measures beyond the stated time frame, in addition to diagnostics and monitoring therapeutic outcomes. The first therapy for acute stroke patients is tPA. However, tPA has the potential to cause bleeding. Hemorrhage transformation was linked to increased BBB permeability in CT angiography studies [147]. Before tPA therapy, CT might be used to determine the risk of bleeding. Gd-micelles, which were created as an MRI contrast agent for tumor imaging, were also employed in a rat model to investigate BBB permeability [26]. The ischemic hemisphere had a substantial contrast in the MRI scans, showing macromolecule permeability via the BBB. The Gd-micelles stayed in the ischemic hemisphere because of their enormous molecular weight. As a result, the Gd-micelles MRI contrast agent could visualize BBB opening to quantify bleeding risk.

These findings show that CT and MRI brain imaging might be used to screen people for brain disorders. Patients are exposed to a significant amount of radiation with the current CT procedure. Nanoparticles have been produced to improve tumor diagnosis
using CT or MRI. As the BBB leaks under specific illness situations, tumor diagnostic nanoparticles, such as Gd-micelles, can be used to diagnose brain disorders. Advanced imageable nanoparticles might potentially reduce the amount of contrast chemicals used in CT and MRI procedures, making them safer.

Nanosized imaging agents and nanocarriers functionalized with imaging agents are the two main types of nanoparticles used in brain imaging. Furthermore, by functionalization with therapeutic drugs, they can be created as theranostic agents [148]. Thus, by using theranostic nanoparticles in disease management, the disadvantages of traditional nanoparticles, such as patient compliance and safety, might be solved [149]. Iron oxide, gold, and manganese oxide are all commonly researched imaging agents.

Because of their unusual physicochemical and superparamagnetic features, iron-oxide-based nanoparticles have attracted a lot of interest as contrast agents. Thus, the utilization of iron-oxide magnetic nanoparticles might enhance medical applications such as cell labeling and sorting, cell transfection, and diagnostic imaging based on MRI, PET, or multimodal imaging [150]. In vitro investigations have shown that theranostic iron oxide nanoparticle surface modification with caffeic acid can be used for glioblastoma MRI and reactive oxygen species formation as a treatment method [151]. Furthermore, iron oxide nanoparticles functionalized with phosphonate polyethylene glycol chains and covalently connected to cyclic RGD were used in vivo for MRI of glioblastoma in mice [152].

As contrast agents for preoperative, intraoperative, and postoperative imaging, gold nanoparticles have piqued the scientific imagination [153]. Furthermore, by adding chemical compounds and targeting molecules to the surface, gold nanoparticles may be employed as multifunctional contrast agents with extended circulation duration, allowing for larger imaging windows [154]. The creation of a target-specific imaging system based on peptide-coated gold nanoparticles for identifying glioma cell biomarkers has validated the imaging agent’s fluorescence signal-based feature [155]. Furthermore, gold nanoparticles may allow for the imaging of implanted stem cells within the brain. One study proposed using gadolinium-labeled DNA gold nanoparticles for MRI tracking of brain stem cells [156].

As gadolinium is highly toxic and is present in all commercially available intravenous agents, researchers have been concentrating their efforts on producing gadolinium-free contrast agents [157,158]. In their study, Eric M. Gale and Peter Caravan reported that manganese is the most promising replacement for gadolinium [158]; manganese oxide nanoparticles were used for in vivo glioblastoma MRI [159].

3.2.8. Liposome-Based Strategies for Effective Drug Delivery across the Blood–Brain Barrier

Liposomes have been studied extensively for their use in drug administration and in vivo bioimaging for the treatment and/or diagnosis of neurological illnesses such as Alzheimer’s, Parkinson’s, stroke, and glioma due to their unique physicochemical properties [160].

Liposomes can include hydrophilic, lipophilic, and hydrophobic medicinal substances due to their distinct physicochemical properties. Hydrophilic chemicals can be found at the interface between the lipid bilayer and the exterior water phase, or they can be entrapped in the watery core of liposomes. Lipophilic or hydrophobic medications are virtually fully captured in the liposomes’ hydrophobic core of lipid bilayers. The usage of cationic lipids also allows for the adsorption of polyanions like DNA and RNA [54,55].

They also exhibit strong biocompatibility and biodegradability, as well as minimal toxicity, drug-targeted delivery, and controlled drug release. The liposome surface can be further changed by adding macromolecules such polymers, polysaccharides, peptides, antibodies, or aptamers to increase blood circulation and brain-specific delivery [54]. Unfortunately, liposomes are not currently used in clinical practice to deliver brain-specific drugs [161,162]. Several, on the other hand, are either licensed for clinical use or are undergoing clinical trials [163,164].

Intranasal administration of rivastigmine [165] or galantamine liposomes [166] was already established to be a practical and effective method of increasing medication bioavail-
ability in the brain. Intranasal administration of liposomes containing quercetin, an antioxidant, was also found to be a viable method of delivery [167]. The usage of quercetin liposomes has been found to reduce neuronal oxidative stress, which is a key factor in the neuropathogenesis of Alzheimer’s disease [168].

Currently existing treatments for Parkinson’s disease are symptom-focused and have little effect on disease progression [169]. Levodopa, often known as L-dopa, is a natural precursor to dopamine that has been utilized in the clinic for several years. Levodopa, on the other hand, cannot be given alone because it is transformed to dopamine by the peripheral dopamine-decarboxylase enzyme, which produces tiredness, nausea, and dyskinesia [170]. This challenge was solved in a latest study that developed liposomes for site-specific transport of levodopa into the CNS [160,171]. Levodopa encapsulated in chlorotoxin-modified stealth liposomes demonstrated to be an effective nanocarrier, raising levodopa content in the substantia nigra and striatum. In a similar manner, intraperitoneal injection of liposome formulations containing anti-PD medicines was found to increase dopamine release in the striatum area [172].

Drug delivery methods for the brain have been identified and developed. Since numerous targeting techniques have been published demonstrating abilities to enter the brain and target the tumor, liposomes have been described as a potentially helpful approach for achieving greater therapeutic effects in the treatment of gliomas.

To overcome the disadvantages of RES (resveratrol) as a free medication, it was placed into PEGylated liposomes (RES–L). The liposome surface was modified with transferrin moieties (Tf–RES–L) to make them cancer-cell-selective since transferrin receptors (TfRs) are up-regulated in GBM. The goal of the liposomal nanomedicines produced in this study was to improve the physico-chemical characteristics of RES and to use the passive and active targeting capabilities of liposomes to treat GBM efficiently. The RES–Ls were stable, had a high drug-loading capacity, had a long in vitro drug-release time, and were simple to scale up [172].

In another study, researchers created a dual-functionalized liposomal delivery system containing transferrin (Tf) for receptor-mediated transcytosis and a cell-penetrating peptide–penetratin (Pen) for increased cell penetration in another investigation (Figure 5). They put doxorubicin and erlotinib inside liposomes to help them go through the BBB and into the glioblastoma tumor. In vitro cytotoxicity and hemocompatibility testing revealed good biocompatibility for in vivo use [173].

![Figure 5](https://example.com/figure5.png)

*Figure 5.* Schematic representation of dual-functionalized (Tf–Pen) liposomes translocation across the BBB, followed by endocytosis into glioblastoma cells. Reprinted with permission from Ref. [173]. Copyright 2019, Elsevier.
3.2.9. Solid-Lipid Nanoparticles

SLNs are lipid-based biocompatible nanocarrier systems made up mostly of lipid or modified lipid nanostructures (triglycerides, fatty acids, or waxes) with diameters ranging from 10 to 1000 nm [174]. Both hydrophilic and lipophilic medicines can be distributed in the solid hydrophobic lipid core of SLNs. They play an important function in the BBB’s reticuloendothelial system (RES) crossing [175]. Due to its solid lipid composition rather than being an aqueous solution, this colloidal nano-carrier was created as a superior replacement for polymeric nanoparticles and liposomes to protect active-drug-counteracting biochemical degradation [174].

Recent studies using SLNs as a carrier system have tried to carry medications over the BBB to the brain. SLNs are a new smart drug delivery system with innovative features for the treatment of neurological disorders, with desirable properties such as nanodiameter range, site-specific targeted delivery (via receptor-mediated transcytosis across brain capillary endothelial cells), physical stability, ability to escape the reticulo-endothelial system, extended blood circulation time, sustained release, and nontoxic, biodegradable, and biocompatible qualities [176].

During intravenous delivery, drug-loaded SLN carriers have a higher accumulation and targeting capability in the brain than in other organs, according to research [177]. SLNs can be given to neuronal locations by oral, inhalational, or parenteral methods as novel delivery vehicles encapsulating active medicines for the treatment of CNS diseases [178]. Following that, SLNs repair neuropathologies by interfering with abnormal signaling pathways as well as metabolism [179]. SLNs loaded with medicines have a number of potential uses in the treatment of CNS illnesses.

They can also distribute the active drug ingredients in a target-specific and regulated way, with fewer potential toxicity risks, because to their unique physicochemical character. Furthermore, SLNs have therapeutic benefits for successful brain medication delivery, including decreased side effects, longer drug half-life, and the potential to improve drug capacity to penetrate the BBB. Despite this, SLN has certain drawbacks, including a smaller drug payload, a complicated physical state of the lipid content, and storage and administration stability issues (gelation, increase in particle size, drug expulsion) [55]. Given the existing disadvantages of SLNs, further research and development is required to make them an optimal CNS drug delivery strategy for treating the widest range of neurological illnesses.

Many research studies on the use of drug-loaded SLNs for the treatment of various CNS disorders, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, brain tumors and cancer, epilepsy, ischemic stroke, and certain neurodegenerative disorders, have been published in recent years and are still ongoing [180].

3.3. Mechanisms by Which Nanosystems Pass through the BBB

Nanoparticles are limited in their ability to penetrate the BBB and, as a result, get access to the brain. Nonetheless, several ways for crossing the BBB by nanoparticles have been tackled, taking advantage of the various physiological factors underpinning this process. The attempted delivery methods include using receptor-mediated endocytosis, transcytosis, or transporters, yet they have not been proved completely efficient for exploiting the full therapeutic and diagnostic potential of nanoparticles [181]. Thus, BBB permeability was sought to be enhanced through the employment of focused ultrasound in synergy with the administration of microbubbles or via different nanoparticles’ surface modification possibilities (e.g., coatings, targeting ligands).

The primary ways that have been reported as promising for nanoparticles permeating the BBB are presented in Table 2.

For a better understanding, the main mechanisms for BBB crossing by nanosystems are visually represented in Figure 6.
| Primary Method          | Sub-Method                  | Description                                                                                                                                                                                                 | References |
|------------------------|-----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Paracellular pathway   | -                           | Ultrasound/microbubbles and osmotic pressure are two methods for disrupting tight junctions between neighboring endothelial cells, both of which increase BBB permeability locally, allowing nanoparticle entrance. However, when the BBB’s homeostatic role is lost, this strategy carries certain hazards, as it would enable uncontrolled entrance of various substances into the brain, potentially resulting in cerebral toxicity. | [182]      |
| Transcellular diffusion| -                           | The simplest transcellular route involves passive diffusion through the cell membrane and cytoplasm. To cross the phospholipidic bilayer of the membrane, nanoparticles must be small enough and at least partially lipophilic. | [183]      |
| Transcytosis pathway   | Adsorptive transcytosis     | The surface characteristics of the nanoparticles make it easier for the nanoparticle and its payload to attach to the endothelial cells’ luminal plasma membrane. Because the plasma membrane of endothelial cells is negatively charged, positively charged nanoparticles are more likely to undergo this process than neutral or negatively charged ones. Nanoparticles coated with wheat germ agglutinin, for example, may be taken up by nerve terminals and retrogradely transported to the CNS by axons. | [184]      |
|                        | Receptor-mediated transcytosis | Where nanoparticles with various ligands on their surfaces can bind to certain receptors and so enhance endocytosis GLUT1, lactoferrin (Lf), transferrin (Tf), or other peptides such as angiopep-2 or Seq12 have all been employed as targets. | [185,186] |
|                        | Clathrin-mediated endocytosis | Endocytotic vesicles up to 200 nm in diameter are formed in clathrin-enriched portions of the cell membrane. Once within the cell, clathrin-coated vesicles fuse together to form an early endosome, which progresses to late endosomes when the intravesicular pH drops and, eventually, lysosomes, triggering cargo destruction. To be an effective delivery agent, the nanoparticle must make it easier for its payload to escape from endosomes before they merge with lysosomes, preventing cargo destruction. | [187]      |
|                        | Caveolin-mediated endocytosis | This occurs in lipid rafts and results in plasma membrane invaginations of roughly 80 nm in size. Following this first stage, caveolin vesicles merge with other caveolin vesicles to form caveosomes, which evade lysosomes and have a variety of fates depending on the cell type. | [187]      |

![Figure 6. Main BBB crossing pathways for nanosystems. Abbreviations: CNS–central nervous system; NCL–nanostructured lipid carriers; NPs–nanoparticles. Reprinted from Ref. [188], Dove Press Ltd., 2015.](image-url)
4. In Vitro and In Vivo Models of BBB for Assessing Drug Delivery

In light of our current understanding of the BBB’s operation, it is reasonable to state that in vivo models are the most well-known and oldest models for simulating the BBB’s structural and functional complexity [189]. The utilization of a living brain in its natural environment is the key benefit. However, adopting in vivo technologies as a high to medium throughput screening procedure is challenging and expensive, hence they are only used in the early phases of drug development [190]. When it comes to the sheer quantity of samples that can be analyzed in a given length of time, the scientific world has finally realized the value of in vitro investigations.

Despite the fact that almost half of all chemicals examined cannot be translated into people, in vitro models are still less expensive and quicker than in vivo studies [191]. A good BBB model should be repeatable, have a realistic architecture, functional expression of transporters, and be simple to set up [189].

In vitro models have been adopted for specific research despite the fact that no known in vitro model can reproduce the NVU of an in vivo system. In general, the goal of in vitro models is to create a highly malleable and controllable environment that allows us to create a system that is slightly similar to a living system in order to assess pathophysiological responses to external stimuli that would otherwise be too difficult to reproduce and characterize in vivo at an early stage of drug development [189]. Over the years, several models have been constructed to investigate the role of BBB in drug delivery; these may be divided into non-cell-based and cell-based in vitro models.

5. Clinical Trials and Products Available on the Market

With a rate of 19.6%, central nervous system trials have increased the most since the beginning of 2021 [192]. Being a topic of high research interest and clinical applicability, it is no surprise that numerous studies concerning BBB have reached the stage of clinical trials. The scientific community has focused on investigating novel methods for enhancing BBB permeability for drug delivery and imaging, bypassing BBB or BBTB in various neurologic conditions, and evaluating the safety of repeated BBB opening (Table 3).

Despite the abundance of recent clinical studies in the field, the market is still scarce in products for enhancing BBB permeability for efficient drug delivery. Nonetheless, several patents have been reported. For instance, Armagen Technology Inc. holds a patent for “Agents for blood–brain barrier delivery” (CA2661042C). Their invention offers compositions, methods, and kits for augmenting transport across the BBB, while allowing agent activity to remain substantially intact once reaching the target. These therapeutic, diagnostic, or research agents (i.e., antibody composition comprising a pharmaceutically acceptable carrier and a fusion antibody) are transported across the BBB via one or more endogenous receptor-mediated transport systems.

The same biotechnology company holds another patent entitled “Fusion proteins for blood–brain barrier delivery” (CA2625293C). This newer invention consists of a composition made of an agent covalently linked at its amino terminus to an antibody that crosses the BBB through an endogenous BBB receptor selected from the group consisting of the insulin receptor, transferrin receptor, leptin receptor, lipoprotein receptor, and the IGF receptor. The reported pharmaceutical composition produces an average elevation of concentration of the agent in the brain of at least 5 ng/g brain following peripheral administration while ensuring a neuroprotective effect.

Armagen has proposed a similar active patent in Japan under the name “Fusion protein for blood–brain barrier transport” (JP628371B2). This invention represents a composition comprising an agent (i.e., erythropoietin) covalently bound by a monoclonal antibody (HYRMAb) and the amino terminus to the human insulin receptor. As in the case of the previously mentioned patent, this formulation also allows an increase in the intracerebral concentration by at least 5 ng/g after peripheral administration while ensuring a neuroprotective effect.
Table 3. Examples of clinical trials investigating BBB-related conditions.

| Study Title                                                                 | Intervention/Treatment                                                                 | Status (as Reported until 5 April 2022)            | ClinicalTrials.gov Identifier |
|----------------------------------------------------------------------------|----------------------------------------------------------------------------------------|---------------------------------------------------|-------------------------------|
| Blood–Brain Barrier Permeability Study in Adults with Meningitis (NM-BBBP)  | Other: ICG-PULSION<br>Device: LiMON, Pulsion Medical Systems<br>Other: Gadolinium (Gadovist, Bayer, Germany) | Terminated                                        | NCT02902588                  |
| The Relevance of the Blood–Brain Barrier to Cognitive Dysfunction and Alzheimer’s Disease | Diagnostic Test: Contrast agent enhanced MRI using Gadovist | Completed                                         | NCT04093882                  |
| Blood–Brain-Barrier Opening Using Focused Ultrasound with IV Contrast Agents in Patients With Early Alzheimer’s Disease (BBB-Alzheimers) | Device: BBB opening                                                                     | Completed                                         | NCT02986932                  |
| Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM              | Procedure: Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB) | Recruiting                                        | NCT03630289                  |
| Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM) | Procedure: Laparoscopically harvested omental free flap | Recruiting                                        | NCT04222309                  |
| Blood–Brain Barrier Opening Using MR-Guided Focused Ultrasound in Patients with Amyotrophic Lateral Sclerosis | Device: Blood–Brain Barrier opening with MRgFUS | Active, not recruiting                            | NCT03321487                  |
| The Level of Blood–Brain Barrier Damage Biomarker in Acute Ischemic Stroke | Diagnostic Test: the level of biomarker in blood                                        | Recruiting                                        | NCT05321225                  |
| Non-invasive Blood–Brain Barrier Opening in Alzheimer’s Disease Patients Using Focused Ultrasound | Device: Neuronavigation-guided single-element focused ultrasound transducer<br>Drug: Definity<br>Other: Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents<br>Other: Positron Emission Tomography (PET) Other: Amyvid | Recruiting                                        | NCT04118764                  |
| Blood–Brain Barrier Penetration of Therapeutic Agents in Human (BRIAN)      | Drug: ODM-104<br>Drug: Paracetamol                                                    | Completed                                         | NCT04571996                  |
| A Study to Evaluate Temporary Blood–Brain Barrier Disruption in Patients with Parkinson’s Disease Dementia | Device: MR Guided Focused Ultrasound<br>Blood Brain Barrier Disruption using FUS<br>Other Name: ExAblate | Active, not recruiting                            | NCT03608553                  |
| ExAblate Blood–Brain Barrier Opening for Treatment of Alzheimer’s Disease | Device: Blood Brain Barrier (BBB) Disruption                                           | Recruiting                                        | NCT03739905                  |
| ExAblate Blood–Brain Barrier (BBB) Disruption for the Treatment of Alzheimer’s Disease | Device: Blood Brain Barrier (BBB) Disruption                                           | Recruiting                                        | NCT03671889                  |
| Blood Brain Barrier Dysfunction and Postoperative Neuropsychiatric Disorders (BBBxs) | Diagnostic Test: Brain Imaging<br>Diagnostic Test: Cognitive Testing<br>Diagnostic Test: Blood Biomarkers | Recruiting                                        | NCT04566562                  |
| Ultrasound-based Blood–Brain Barrier Opening and Albumin-bound Paclitaxel for Recurrent Glioblastoma (SC1/ABX) | Device: Sonication for opening of blood–brain barrier<br>Drug: Chemotherapy, albumin-bound paclitaxel | Recruiting                                        | NCT04528680                  |
| Safety Study of the Repeated Opening of the Blood–Brain Barrier with the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients (SONOKID) | Device: SonoCloud® (9 transducers)                                                    | Not yet recruiting                               | NCT05293197                  |
| Developing Advanced Blood–Brain Barrier Permeability Imaging for Early AD | Device: GRASP DCE-MRI<br>Device: 3T Brain Scan                                          | Recruiting                                        | NCT03389698                  |

In addition, it can be expected that undergoing clinical trials may soon offer promising results, leading to the entrance into the market and/or clinical practice of novel performant devices, procedures, and drug formulations for enhancing BBB permeability without compromising patients’ safety.
6. Perspectives and Future Research Directions

Pre-clinical studies have revealed focused ultrasound as a viable therapeutic approach for recurring, non-invasive, and transient BBB opening for the therapy of CNS disorders, based on significant proof-of-concept in multiple animal species. The efficacy of ultrasound-mediated BBB permeability for the controlled and regulated transportation of drugs, such as antibodies, to the brain, as well as larger vehicles for drug delivery applications, such as liposomes, polymeric nanoparticles, and even viruses, was also shown in these studies. This opens the door to using this modality to deliver potential new treatments such as checkpoint blockade antibodies for extracranial tumors, modulating protein expression using transcription factor genes, micro-RNAs, and shRNAs to target immune signaling in diseased tissue, and repurposing drugs that have performed poorly, for example, because they did not reach their goal in therapeutic quantities.

For optimal BBB rupture, a multitude of clinical studies have demonstrated appropriate parameters for ultrasound parameters such as acoustic frequency, center frequency, pulse repetition frequency, ultrasound pulse duration, and microbubble injection. However, the majority of these investigations have been carried out on tiny animals. Until this modality can be effectively integrated to larger animals and, sooner or later, to humans, a multitude of technical difficulties must be addressed, including the fact that the heterogeneity of the skull can induce ultrasound beam disturbance and pressure attenuation, the need for standardized ultrasound techniques and trying to report, and quantitative metrics for establishing BBB opening. Furthermore, current microbubbles have not been specifically designed for BBB opening using ultrasound.

This emphasizes the need for creating and optimizing standardized microbubbles. In order to deliver tailored therapy while reducing adverse effects, translational investigations are necessary for enhanced real-time monitoring of the effects of ultrasound on the BBB. Aside from these physical constraints, there are a lot of biological unknown factors, such as the brain’s heterogeneity and the NVU’s cellular components’ responses to ultrasound. Cellular NVU approaches relying on patient-derived ECs should aid in better understanding the BBB’s molecular impacts. In addition, research employing new and improved BBB models will give information on cellular interconnections and signals in both healthy and diseased conditions.

More study is needed to better understand how skull and brain characteristics, as well as microbubble properties, influence BBB permeability and how they alter with aging and disorder, as well as the ability of ultrasound in enhanced cellular and animal models of brain diseases.

Liposomes, nanoparticles, and dendrimers have shown promising results following technological advancements. Alternative routes beyond the BBB have also showed great commercial promise. Furthermore, in order to achieve a beneficial brain-targeted drug-delivery system, some fundamental concerns must be addressed in the near future, such as (1) factors affecting the system’s in vivo performance should be well-explained and evaluated (for example, in in vivo studies describing the treatment of glioblastoma, the BBB in tumors is less tight than in healthy brain tissue; this may influence the study’s outcome), (2) more focus should be put on the development of novel drug delivery systems, (3) targeting the efficiency of such systems before clinical application requires significant improvement; (4) hydrophobic drugs may leak from the delivery system and then enter the brain (and thus, proof of drug penetration into the brain does not (necessarily) imply proof of delivery system penetration); and (5) a uniform method of preparation for the development of a nanoparticulate system should be developed to achieve a more homogeneous system. The key to developing a successful delivery system is to consider not just effective brain targeting formulations, but also less toxic and safe medications in order to provide patients with a better and healthier future.
7. Conclusions

This review has analyzed current medicine delivery techniques to the brain in the last five years. A thorough understanding of BBB disruption is required to build successful medication delivery methods for brain illnesses. Recent developments in research have shown the permeable BBB in brain damage and the processes of BBB control. In addition to well-established technologies like viral vectors and nanoparticles, novel non-invasive techniques like MEUS and TMS have just been developed to temporarily open the BBB and increase medicine absorption in the brain. It is reasonable to suppose that new delivery systems will help in the diagnosis of brain illnesses. Along with a better understanding of the leaky BBB, previously developed nanoparticles targeting tumors via the EPR effect could be exploited to treat brain diseases. Gliomas come in a wide variety of sizes and shapes, with typical permeability at the perimeter. As a result, a combination of approaches for accessing both permeable and non-permeable BBBSs may be necessary.

Furthermore, further studies are needed on the dynamics of BBB disruption, which will aid in the design of adequate delivery systems that take advantage of the leaky BBB. Another crucial topic that warrants additional research is the effect of aging on BBB dysfunctions. Brain medication delivery systems that have considered the effects of aging and have been evaluated in animals of various ages are uncommon in the literature. In conclusion, the intricacy of the BBB necessitates more extensive investigations on delivery tactics. Still, it may also provide a unique opportunity to build effective delivery systems to treat diverse brain illnesses.

**Author Contributions:** All authors have participated in review writing and revision. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Asaduzzaman, S.; Chakma, R.; Rehana, H.; Raihan, M. Regulatory Gene Network Pathway among Brain Cancer and Associated Disease: A Computational Analysis. *Biointerface Res. Appl. Chem.* 2021, 11, 12973–12984. [CrossRef]
2. Lingineni, K.; Belekar, V.; Tangadpalliwar, S.R.; Garg, P. The role of multidrug resistance protein (MRP-1) as an active efflux transporter on blood-brain barrier (BBB) permeability. *Mol. Divers.* 2017, 21, 355–365. [CrossRef] [PubMed]
3. Goyal, D.; Shuaib, S.; Mann, S.; Goyal, B. Rationally Designed Peptides and Peptidomimetics as Inhibitors of Amyloid-beta (A beta) Aggregation: Potential Therapeutics of Alzheimer’s Disease. *Acs Comb. Sci.* 2017, 19, 55–80. [CrossRef]
4. Pardridge, W.M. Transport of small molecules through the blood-brain-barrier—biology and methodology. *Adv. Drug Deliv. Rev.* 1995, 15, 5–36. [CrossRef] [PubMed]
5. McCaffrey, G.; Davis, T.P. Physiology and pathophysiology of the blood-brain barrier: P-glycoprotein and occludin culling as therapeutic targets to optimize central nervous system drug delivery. *J. Investig. Med. Off. Publ. Am. Fed. Clin. Res.* 2012, 60, 1131–1140. [CrossRef] [PubMed]
6. Banks, W.A. From blood-brain barrier to blood-brain interface: New opportunities for CNS drug delivery. *Nat. Rev. Drug Discov.* 2016, 15, 275–292. [CrossRef] [PubMed]
7. Ishola, A.A.; Oyinloye, B.E.; Ajiboye, B.O.; Kappo, A.P. Molecular Docking Studies of Flavonoids from Andrographis paniculata as Potential Acetylcholinesterase, Butyrylcholinesterase and Monoamine Oxidase Inhibitors Towards the Treatment of Neurodegenerative Diseases. *Biointerface Res. Appl. Chem.* 2021, 11, 9871–9879. [CrossRef]
8. Neuwelt, E.; Abbott, N.; Abrey, L.; Banks, W.A.; Blakley, B.; Davis, T.; Engelhardt, B.; Grammas, P.; Nedergaard, M.; Nutt, J.; et al. Strategies to advance translational research into brain barriers. *Lancet Neurol.* 2008, 7, 84–96. [CrossRef]
9. Circulation and the Central Nervous System Anatomy and Physiology I. Available online: https://courses.lumenlearning.com/ap1/chapter/circulation-and-the-central-nervous-system/ (accessed on 3 December 2021).
10. De Luca, C.; Colangelo, A.M.; Alberghina, L.; Papa, M. Neuro-Immune Hemostasis: Homeostasis and Diseases in the Central Nervous System. *Front. Cell. Neurosci.* 2018, 12, 459. [CrossRef]
11. Profaci, C.P.; Munji, R.N.; Pulido, C.K.; Daneman, R. The blood-brain barrier in health and disease: Important unanswered questions. J. Exp. Med. 2020, 217, e20190062. [CrossRef]

12. Abbott, N.J.; Ronnback, L.; Hansson, E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 2006, 7, 41–53. [CrossRef]

13. Zlokovic, B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57, 178–201. [CrossRef]

14. Al Rihani, S.B.; Darakjian, L.L.; Deodhar, M.; Dow, P.; Turgeon, J.; Michaud, V. Disease-Induced Modulation of Drug Transporters at the Blood–Brain Barrier Level. Int. J. Mol. Sci. 2021, 22, 3742. [CrossRef]

15. Pehlivani, S.B. Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases. Pharm. Res. 2013, 30, 2499–2511. [CrossRef]

16. Komarova, Y.A.; Kruse, K.; Mehta, D.; Malik, A.B. Protein Interactions at Endothelial Junctions and Signaling Mechanisms Regulating Endothelial Permeability. Circ. Res. 2017, 120, 179–206. [CrossRef] [PubMed]

17. Lecuyer, M.A.; Saint-Laurent, O.; Bourbonniere, L.; Larouche, S.; Larochelle, C.; Michel, L.; Charabati, M.; Abadier, M.; Zandee, S.; Jahromi, N.H.; et al. Dual role of ALCAM in neuroinflammation and blood-brain barrier homeostasis. Proc. Natl. Acad. Sci. USA 2017, 114, E524–E533. [CrossRef]

18. Banks, W.A. Characteristics of compounds that cross the blood-brain barrier. BMC Neurol. 2009, 9 (Suppl. 1), S3. [CrossRef]

19. Kadry, H.; Noorani, B.; Cucullo, L. A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS 2020, 17, 69. [CrossRef]

20. Koepsell, H. Glucose transporters in brain in health and disease. Pflug. Arch. Eur. J. Physiol. 2020, 472, 1299–1343. [CrossRef]

21. Ballabh, P.; Braun, A.; Nedergaard, M. The blood-brain barrier: An overview—Structure, regulation, and clinical implications. Neurobiol. Dis. 2004, 16, 1–13. [CrossRef]

22. Mage, I.; Meyer, A.H.; Li, J.H.; Lenter, M.; Hildebrandt, T.; Leparc, G.; Wood, M.J.A. Targeting blood-brain-barrier transcytosis—perspectives for drug delivery. Neuropharmacology 2017, 120, 4–7. [CrossRef] [PubMed]

23. Rahman, M.M.; Ferdous, K.S.; Ahmed, M. Emerging Promise of Nanoparticle-Based Treatment for Parkinson’s disease. Biointerface Res. Appl. Chem. 2020, 10, 7135–7151. [CrossRef]

24. Haghighatseir, N.; Ashrafi, H.; Rafiei, P.; Azadi, A. Dexamethasone ameliorates Alzheimer’s pathological condition via inhibiting NF-kappa B and mTOR signaling pathways. Biointerface Res. Appl. Chem. 2020, 10, 5792–5796. [CrossRef]

25. Archie, S.R.; Al Shoyaib, A.; Cucullo, L. Blood-Brain Barrier Dysfunction in CNS Disorders and Putative Therapeutic Targets: An Overview. Pharmaceutics 2021, 13, 1779. [CrossRef]

26. Shiraishi, K.; Wang, Z.J.; Kokuryo, D.; Aoki, I.; Yokoyama, M. A polymeric micelle magnetic resonance imaging (MRI) contrast agent reveals blood-brain barrier (BBB) permeability for macromolecules in cerebral ischemia-reperfusion injury. J. Control. Release 2017, 253, 165–171. [CrossRef]

27. Di Pardo, A.; Amico, E.; Scalabri, F.; Pepe, G.; Castaldo, S.; Elifani, F.; Capocci, L.; De Sanctis, C.; Comerci, L.; Pompeo, F.; et al. Impairment of blood-brain barrier is an early event in R6/2 mouse model of Huntington Disease. Sci. Rep. 2017, 7, 41316. [CrossRef]

28. Gao, X.P.; Kouklis, P.; Xu, N.; Minshall, R.D.; Sandoval, R.; Vogel, S.M.; Malik, A.B. Reversibility of increased microvessel permeability in response to VE-cadherin disassembly. Am. J. Physiol. Lung Cell. Mol. Physiol. 2000, 279, L1218–L1225. [CrossRef]

29. Rosenberg, G.A. Blood-Brain Barrier Permeability in Aging and Alzheimer’s Disease. J. Prev. Alzheimers Dis. 2014, 1, 138–139. [CrossRef]

30. Rasouli, R.; Zaaeri, F.; Rajabi, A.B.; Darbandi-Azar, A.; Faridi-Majidi, R.; Ardestani, M.S. Tc-99m-Anionic Linear Globular Dendrimer-G2-Phenylalanine Conjugate: Novel Brain Tumor SPECT Imaging. Biointerface Res. Appl. Chem. 2021, 11, 11244–11255. [CrossRef]

31. van Tellingen, O.; Yetkin-Arik, B.; de Gooijer, M.C.; Wesseling, P.; Wurdinger, T.; de Vries, H.E. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist. Updates 2015, 19, 1–12. [CrossRef]

32. Sharma, H.S.; Muresanu, D.F.; Castellani, R.J.; Nozari, A.; Lafuente, J.V.; Tian, Z.R.; Sahib, S.; Bryukhovetskiy, I.; Buzoianu, A.D.; et al. Chapter One—Pathophysiology of blood-brain barrier in brain tumor. Novel therapeutic advances using nanomedicine. In International Review of Neurobiology; Bryukhovetskiy, I., Sharma, A., Zhang, Z., Sharma, H.S., Eds.; Academic Press: Cambridge, MA, USA, 2020; Volume 151, pp. 1–66. [CrossRef]

33. Wanjale, M.V.; Kumar, G.S.V. Peptides as a therapeutic avenue for nanocarrier-aided targeting of glioma. Expert Opin. Drug Deliv. 2017, 14, 811–824. [CrossRef] [PubMed]

34. Kooij, G.; van Horssen, J.; Bandaru, V.V.; Haughey, N.J.; de Vries, H.E. The Role of ATP-Binding Cassette Transporters in Neuro-Inflammation: Relevance for Bioactive Lipids. Front. Pharmacol. 2012, 3, 74. [CrossRef] [PubMed]

35. Lewinson, O.; Orelle, C.; Seeger, M.A. Structures of ABC transporters: Handle with care. Annu. Rev. Biochem. 2020, 89, 605–636. [CrossRef]
38. Robey, R.W.; Pluchino, K.M.; Hall, M.D.; Fojo, A.T.; Bates, S.E.; Gottesman, M.M. Revisiting the role of ABC transporters in multidrug-resistant cancer. *Nat. Rev. Cancer* 2018, 18, 452–464. [CrossRef]

39. Hotz, J.M.; Thomas, J.R.; Katz, E.N.; Robey, R.W.; Horibata, S.; Gottesman, M.M. ATP-binding cassette transporters at the zebrafish blood-brain barrier and the potential utility of the zebrafish as an in vivo model. *Cancer Drug Resist.* 2021, 4, 620–633. [CrossRef]

40. Bugde, P.; Biswas, R.; Merien, F.; Lu, J.; Liu, D.X.; Chen, M.W.; Zhou, S.F.; Li, Y. The therapeutic potential of targeting ABC transporters to combat multi-drug resistance. *Expert Opin. Ther. Targets* 2017, 21, 511–530. [CrossRef]

41. Tournier, N.; Goutal, S.; Mairinger, S.; Hernandez-Lozano, I.; Filipp, T.; Sauberer, M.; Caille, F.; Breuil, L.; Stanek, J.; Freeman, A.F.; et al. Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate C-11 erlotinib. *J. Cereb. Blood Flow Metab.* 2021, 41, 1634–1646. [CrossRef]

42. Dash, R.P.; Babu, R.J.; Srinivas, N.R. Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies. *Eur. J. Drug Metab. Pharmacokinet.* 2017, 42, 915–933. [CrossRef]

43. Bauer, M.; Wulkersdorfer, B.; Karch, R.; Philippe, C.; Jager, W.; Stanek, J.; Wadsak, W.; Hacker, M.; Zeitlinger, M.; Langer, O. Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-C-11 verapamil in elderly vs. young subjects. *Br. J. Clin. Pharmacol.* 2017, 83, 1991–1999. [CrossRef] [PubMed]

44. Gomez-Zepeda, D.; Taghi, M.; Scherrmann, J.M.; Declives, X.; Menet, M.C. ABC Transporters at the Blood-Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliaomas. *Pharmaceutics* 2020, 12, 20. [CrossRef] [PubMed]

45. Lai, J.I.; Tseng, Y.J.; Chen, M.H.; Huang, C.Y.F.; Chang, P.M.H. Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics. *Front. Oncol.* 2020, 10, 2336. [CrossRef] [PubMed]

46. Nagaya, Y.; Katayama, K.; Kusuhara, H.; Nozaki, Y. Impact of P-Glycoprotein-Mediated Active Efflux on Drug Distribution into Lumbar Cerebrospinal Fluid in Nonhuman Primates. *Drug Metab. Dispos.* 2020, 48, 1183–1190. [CrossRef] [PubMed]

47. Dong, X.W. Current Strategies for Brain Drug Delivery. *Theranostics* 2018, 8, 1481–1493. [CrossRef]

48. Burgess, A.; Hynynen, K. Drug delivery across the blood-brain barrier using focused ultrasound. *Expert Opin. Drug Deliv.* 2014, 11, 711–721. [CrossRef]

49. Vagner, T.; Dvorzhak, A.; Wojtowicz, A.M.; Harms, C.; Grantyn, R. Systemic application of AAV vectors targeting GFAP-expressing astrocytes in ZQ175-KI Huntington’s disease mice. *Mol. Cell. Neurosci.* 2016, 77, 76–86. [CrossRef] [PubMed]

50. Check, E. Gene therapy put on hold as third child develops cancer. *Nature* 2005, 433, 561. [CrossRef]

51. Sarin, H. Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors. *J. Transl. Med.* 2009, 7, 77. [CrossRef]

52. Yang, T.Z.; Fogarty, B.; LaForge, B.; Aziz, S.; Pham, T.; Lai, L.N.; Bai, S.H. Delivery of Small Interfering RNA to Inhibit Vascular Endothelial Growth Factor in Zebrafish Using Natural Brain Endothelia Cell-Secreted Exosome Nanovesicles for the Treatment of Brain Cancer. *AAPS J.* 2017, 19, 475–486. [CrossRef]

53. Thomas, F.C.; Taskar, K.; Rudraraju, V.; Goda, S.; Thorsheim, H.R.; Gaasch, J.A.; Mittapalli, R.K.; Palmieri, D.; Steeg, P.S.; Lockman, P.R.; et al. Uptake of ANG1005, A Novel Paclitaxel Derivative, Through the Blood-Brain Barrier into Brain and Experimental Brain Metastases of Breast Cancer. *Pharm. Res.* 2009, 26, 2486–2494. [CrossRef] [PubMed]

54. Has, C.; Suntihar, P. A comprehensive review on recent preparation techniques of liposomes. *J. Liposome Res.* 2020, 30, 336–365. [CrossRef] [PubMed]

55. Bayon-Cordero, L.; Alkorta, I.; Arana, L. Application of Solid Lipid Nanoparticles to Improve the Efficiency of Anticancer Drugs. *Nanomaterials* 2019, 9, 474. [CrossRef] [PubMed]

56. Patel, M.M.; Patel, B.M. Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain. *CNS Drugs* 2017, 31, 109–133. [CrossRef]

57. Zhang, X.; Liu, X.D.; Hu, G.Y.; Zhang, G.Y.; Zhao, G.; Shi, M. Ginsenoside Rd attenuates blood-brain barrier damage by suppressing proteasome-mediated signaling after transient forebrain ischemia. *Neuroreport* 2020, 31, 466–472. [CrossRef]

58. Poznanski, P.; Lesniak, A.; Korostynski, M.; Sacharczuk, M. Ethanol consumption following mild traumatic brain injury is related to blood-brain barrier permeability. *Addict. Biol.* 2020, 25, e12683. [CrossRef]

59. Li, Z.G.; Wang, Z.Y.; Xue, K.B.; Wang, Z.S.; Guo, C.; Qian, Y.; Li, X.Q.; Wei, Y.J. High concentration of blood cobalt is associated with the impairment of blood-brain barrier permeability. *Front. Oncol.* 2018, 8, 119–206. [CrossRef]

60. Fan, C.H.; Liu, H.L.; Huang, C.Y.; Ma, Y.J.; Yen, T.C.; Yeh, C.K. Detection Of Intracerebral Hemorrhage And Transient Blood-Supply Shortage In Focused-Ultrasound-Induced Blood-Brain Barrier Disruption By Ultrasound Imaging. *Ultrasound Med. Biol.* 2012, 38, 1372–1382. [CrossRef]

61. Li, Y.J.; Wu, M.X.; Zhang, N.S.; Tang, C.Y.; Jiang, P.; Liu, X.; Yan, F.; Zheng, H.R. Mechanisms of enhanced anti glioma efficacy of polysorbate 80-modified paclitaxel-loaded PLGA nanoparticles by focused ultrasound. *J. Cell. Mol. Med.* 2018, 22, 4171–4182. [CrossRef]

62. Yoshida, Y.; Sejimo, Y.; Kurachi, M.; Ishizaki, Y.; Nakano, T.; Takahashi, A. X-ray irradiation induces disruption of the blood-brain barrier with localized changes in claudin-5 and activation of microglia in the mouse brain. *Neurochem. Int.* 2018, 119, 199–206. [CrossRef]

63. Sharabi, S.; Bresler, Y.; Ravid, O.; Shemes, C.; Atrakchi, D.; Schnaid-Beer, M.; Gosselet, F.; Dehouch, L.; Last, D.; Guez, D.; et al. Transient blood-brain barrier disruption is induced by low pulsed electrical fields in vitro: An analysis of permeability and trans-endothelial electric resistivity. *Drug Deliv.* 2019, 26, 459–469. [CrossRef]
64. Giri, P.; Mittal, L.; Camarillo, I.G.; Sundararajan, R. Analysis of Pathways in Triple-Negative Breast Cancer Cells Treated with the Combination of Electrochemotherapy and Cisplatin. *Biointerface Res. Appl. Chem.* **2021**, *11*, 13453–13464. [CrossRef]

65. Hjouj, M.; Last, D.; Guez, D.; Daniels, D.; Sharabi, S.; Lavee, J.; Rubinszky, B.; Mardor, Y. MRI Study on Reversible and Irreversible Electroporation Induced Blood Brain Barrier Disruption. *PLoS ONE* **2012**, *7*, e42817. [CrossRef] [PubMed]

66. Sharabi, S.; Last, D.; Guez, D.; Daniels, D.; Hjouj, M.I.; Salomon, S.; Maor, E.; Mardor, Y. Dynamic effects of point source electroporation on the rat brain tissue. *Bioelectrochemistry* **2014**, *99*, 30–39. [CrossRef] [PubMed]

67. Lopez-Quintero, S.V.; Datta, A.; Amaya, R.; Elwassif, M.; Bikson, M.; Tarbell, J.M. DBS-relevant electric fields increase hydraulic conductivity of in vitro endothelial monolayers. *J. Neural Eng.* **2010**, *7*, 16005. [CrossRef] [PubMed]

68. Bonakdar, M.; Graybill, P.M.; Davalos, R.V. A microfluidic model of the blood-brain barrier to study permeabilization by pulsed electric fields. *Rsc. Adv.* **2017**, *7*, 42811–42818. [CrossRef]

69. Calias, P.; Banks, W.A.; Begley, D.; Scarpa, M.; Dickson, P. Intrathecal delivery of protein therapeutics to the brain: A critical reassessment. *Pharmacol. Ther.* **2014**, *144*, 114–122. [CrossRef]

70. Scarpa, M.; Bellettato, C.M.; Lampe, C.; Leader, D.; Begley, D.J. Neuronopathic lysosomal storage disorders: Approaches to treat the central nervous system. *Best Pract. Res. Clin. Endocrinol. Metab.* **2015**, *29*, 159–171. [CrossRef]

71. Kakissis, E.D.; Muenzer, J.; Miller, G.E.; Waber, L.; Belmont, J.; Page, M.; Lutsky, B.; Phillips, J.; Doroshov, R.; Walot, I.; et al. Enzyme-replacement therapy in mucopolysaccharidosis I. *N. Engl. J. Med.* **2001**, *344*, 182–188. [CrossRef]

72. Dickson, P.I.; Chen, A.H. Intrathecal enzyme replacement therapy for mucopolysaccharidosis I: Translating success in animal models to patients. *Curr. Pharm. Biotechnol.* **2011**, *12*, 946–955. [CrossRef]

73. King, B.; Setford, M.L.; Hassiotis, S.; Trim, P.; Tucker, J.N.; Hattersley, K.; Snel, M.F.; Hopwood, J.J.; Hemsley, K.M. Low-dose, continual enzyme delivery ameliorates some aspects of established brain disease in a mouse model of a childhood-onset neurodegenerative disorder. *Exp. Neurol.* **2016**, *278*, 11–21. [CrossRef] [PubMed]

74. Winner, L.K.; Marshall, N.R.; Jolly, R.D.; Trim, P.J.; Duplock, S.; Tucker, J.N.; Hattersley, K.; Snel, M.F.; Hopwood, J.J.; Hemsley, K.M. Evidence for a role of transforming growth factor-beta. *Lab. Investig.* **2000**, *80*, 973–980. [CrossRef] [PubMed]

75. Muenzer, J.; Hendriksz, C.J.; Fan, Z.; Sharabi, S.; Last, D.; Hjouj, M.I.; Salomon, S.; Maor, E.; Mardor, Y. Dynamic effects of point source electroporation on the rat brain tissue. *Bioelectrochemistry* **2014**, *99*, 30–39. [CrossRef] [PubMed]

76. Schally, A.V.; Nagy, A. Chemotherapy targeted to cancers through tumoral hormone receptors. *Trends Endocrinol. Metab.* **2004**, *15*, 300–310. [CrossRef]

77. Elmagbary, N.O.; Egleton, R.D.; Palian, M.M.; Lowery, J.J.; Schmid, W.R.; Davis, P.; Navratilova, E.; Dhanasekaran, M.; Keyari, C.M.; Yamamura, H.I.; et al. Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides. *J. Pharmacol. Exp. Ther.* **2004**, *311*, 290–297. [CrossRef]

78. Palian, M.M.; Boguslavsky, V.I.; O’Brien, D.F.; Pelt, R. Glycopeptide-membrane interactions: Glycosyl enkephalin analogues adopt turn conformations by NMR and CD in amphipathic media. *J. Am. Chem. Soc.* **2003**, *125*, 5823–5831. [CrossRef]

79. Juillerat-Janneret, L.; Lohn, S.; Hamou, M.F.; Pinet, F. Regulation of aminopeptidase A in human brain tumour vasculature: Evidence for a role of transforming growth factor-beta. *Lab. Investig.* **2000**, *80*, 973–980. [CrossRef]

80. Egleton, R.D.; Davis, T.P. Development of neuropeptide drugs that cross the blood-brain barrier. *NeuroRx J. Am. Soc. Exp. Neuro Ther.* **2005**, *2*, 44–53. [CrossRef] [PubMed]

81. Zhang, W.; Liu, Q.Y.; Haqqani, A.S.; Leclerc, S.; Liu, Z.; Fauteux, F.; Baumann, E.; Delaney, C.E.; Ly, D.; Star, A.T.; et al. Differential expression of receptors mediating receptor-mediated transcytosis (RMT) in brain microvessels, brain parenchyma and peripheral tissues of the mouse and the human. *Fluids Barriers CNS* **2020**, *17*, 47. [CrossRef] [PubMed]

82. Smith, N.M.; Gachullincova, I.; Ho, D.W.; Bailey, C.; Bartlett, C.A.; Norret, M.; Murphy, J.; Buckley, A.; Rigby, P.J.; House, M.J.; et al. An Unexpected Transient Breakdown of the Blood Brain Barrier Triggers Passage of Large Intravenously Administered Nanoparticles. *Sci. Rep.* **2016**, *6*, 22595. [CrossRef] [PubMed]

83. Nilaver, G.; Muldoon, L.L.; Kroll, R.A.; Pagel, M.A.; Breakefield, X.O.; Davidson, B.L.; Neuwelt, E.A. Delivery Of Herpesvirus And Adenovirus To Nude Rat Intracerebral Tumors After Osmotic Blood-Brain-Barrier Disruption. *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 9829–9833. [CrossRef] [PubMed]

84. Louboutin, J.P.; Chekmasova, A.A.; Marusich, E.; Chowdhury, J.R.; Strayer, D.S. Efficient CNS gene delivery by intravenous injection. *Nat. Methods* **2010**, *7*, 905–907. [CrossRef]
89. Fu, H.Y.; Muenzer, J.; Samulski, R.J.; Breese, G.; Siffford, J.; Zeng, X.H.; McCarty, D.M. Self-complementary adeno-associated virus serotype 2 vector: Global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. *Mol. Ther.* 2003, 8, 911–917. [CrossRef]

90. McCarty, D.M.; DiRosario, J.; Gulaid, K.; Muenzer, J.; Fu, H. Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIIB mice. *Gene Ther.* 2009, 16, 1340–1352. [CrossRef]

91. Fu, H.Y.; Bartz, J.D.; Stephens, R.L.; McCarty, D.M. Peripheral Nervous System Neuropathology and Progressive Sensory Impairments in a Mouse Model of Mucopolysaccharidosis IIIB. *PloS ONE* 2012, 7, e49592. [CrossRef]

92. Terstappen, G.C.; Meyer, A.H.; Bell, R.D.; Zhang, W.D. Strategies for delivering therapeutics across the blood-brain barrier. *Nat. Rev. Drug Discov.* 2021, 20, 362–383. [CrossRef]

93. Felix, M.S.; Borloz, E.; Metwally, K.; Dauba, A.; Larrat, B.; Matagne, V.; Ehinger, Y.; Villard, L.; Novell, A.; Mensah, S.; et al. Ultrasound-Mediated Blood-Brain Barrier Opening Improves Whole Brain Gene Delivery in Mice. *Pharmaceutics* 2021, 13, 1245. [CrossRef]

94. Huang, L.; Wu, J.; Wu, Y.Q.; Tian, Y.; Yao, Y.Z.; Yao, S.; Ji, X.Y.; Wang, S.J.; Su, Z.L.; Xu, H.X. Challenges in adeno-associated virus-based treatment of central nervous system diseases through systemic injection. *Life Sci.* 2021, 270, 119412. [CrossRef] [PubMed]

95. Elliott, R.O.; He, M. Unlocking the Power of Exosomes for Crossing Biological Barriers in Drug Delivery. *Pharmaceutics* 2021, 13, 122. [CrossRef] [PubMed]

96. Pulgar, V.M. Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges. *Front. Neurosci.* 2019, 12, 1019. [CrossRef] [PubMed]

97. Mardpour, S.; Hamidieh, A.A.; Taleahmad, S.; Sharifzad, F.; Taghikhani, A.; Baharvand, H. Interaction between mesenchymal stromal cell-derived extracellular vesicles and immune cells by distinct protein content. *J. Cell. Physiol.* 2019, 234, 8249–8258. [CrossRef]

98. Li, C.J.; Fang, Q.H.; Liu, M.L.; Lin, J.N. Current understanding of the role of Adipose-derived Extracellular Vesicles in Metabolic Homeostasis and Diseases: Communication from the distance between cells/tissues. *Theranostics* 2020, 10, 7422–7435. [CrossRef]

99. Alexander, M.; Ramstead, A.G.; Bauer, K.M.; Lee, S.-H.; Runtsch, M.C.; Wallace, J.; Huffaker, T.B.; Larsen, D.K.; Tolmachova, T.; Seabra, M.C.; et al. Rab27-Dependent Exosome Production Inhibits Chronic Inflammation and Enables Acute Responses to Inflammatory Stimuli. *J. Immunol.* 2017, 199, 3559–3570. [CrossRef]

100. Dalkara, T.; Gursoy-Ozdemir, Y.; Yemisci, M. Brain microvascular pericytes in health and disease. *Acta Neuropathol.* 2011, 122, 1–9. [CrossRef] [PubMed]

101. Alexander, M.; Ramstead, A.G.; Bauer, K.M.; Lee, S.-H.; Runtsch, M.C.; Wallace, J.; Huffaker, T.B.; Larsen, D.K.; Tolmachova, T.; Seabra, M.C.; et al. Rab27-Dependent Exosome Production Inhibits Chronic Inflammation and Enables Acute Responses to Inflammatory Stimuli. *J. Immunol.* 2017, 199, 3559–3570. [CrossRef]

102. Terstappen, G.C.; Meyer, A.H.; Bell, R.D.; Zhang, W.D. Strategies for delivering therapeutics across the blood-brain barrier. *Nat. Rev. Drug Discov.* 2021, 20, 362–383. [CrossRef]

103. Penfornis, P.; Vallabhaneni, K.C.; Whitt, J.; Pochampally, R. Extracellular vesicles as carriers of microRNA, proteins and lipids in tumor microenvironment. *Int. J. Cancer* 2017, 199, 3559–3570. [CrossRef]

104. Armstrong, J.P.K.; Holme, M.N.; Stevens, M.M. Re-Engineering Extracellular Vesicles as Smart Nanoscale Therapeutics. *ACS Nano* 2017, 11, 69–83. [CrossRef]

105. Ly, C.; Fang, Q.H.; Liu, M.L.; Lin, J.N. Current understanding of the role of Adipose-derived Extracellular Vesicles in Metabolic Homeostasis and Diseases: Communication from the distance between cells/tissues. *Theranostics* 2020, 10, 7422–7435. [CrossRef]

106. Li, C.J.; Fang, Q.H.; Liu, M.L.; Lin, J.N. Current understanding of the role of Adipose-derived Extracellular Vesicles in Metabolic Homeostasis and Diseases: Communication from the distance between cells/tissues. *Theranostics* 2020, 10, 7422–7435. [CrossRef]

107. Mardpour, S.; Hamidieh, A.A.; Taleahmad, S.; Sharifzad, F.; Taghikhani, A.; Baharvand, H. Interaction between mesenchymal stromal cell-derived extracellular vesicles and immune cells by distinct protein content. *J. Cell. Physiol.* 2019, 234, 8249–8258. [CrossRef]

108. Li, C.J.; Fang, Q.H.; Liu, M.L.; Lin, J.N. Current understanding of the role of Adipose-derived Extracellular Vesicles in Metabolic Homeostasis and Diseases: Communication from the distance between cells/tissues. *Theranostics* 2020, 10, 7422–7435. [CrossRef]

109. Alexander, M.; Ramstead, A.G.; Bauer, K.M.; Lee, S.-H.; Runtsch, M.C.; Wallace, J.; Huffaker, T.B.; Larsen, D.K.; Tolmachova, T.; Seabra, M.C.; et al. Rab27-Dependent Exosome Production Inhibits Chronic Inflammation and Enables Acute Responses to Inflammatory Stimuli. *J. Immunol.* 2017, 199, 3559–3570. [CrossRef]

110. Dalkara, T.; Gursoy-Ozdemir, Y.; Yemisci, M. Brain microvascular pericytes in health and disease. *Acta Neuropathol.* 2011, 122, 1–9. [CrossRef] [PubMed]

111. Alexander, M.; Ramstead, A.G.; Bauer, K.M.; Lee, S.-H.; Runtsch, M.C.; Wallace, J.; Huffaker, T.B.; Larsen, D.K.; Tolmachova, T.; Seabra, M.C.; et al. Rab27-Dependent Exosome Production Inhibits Chronic Inflammation and Enables Acute Responses to Inflammatory Stimuli. *J. Immunol.* 2017, 199, 3559–3570. [CrossRef]

112. Terstappen, G.C.; Meyer, A.H.; Bell, R.D.; Zhang, W.D. Strategies for delivering therapeutics across the blood-brain barrier. *Nat. Rev. Drug Discov.* 2021, 20, 362–383. [CrossRef]
114. Hama, H.; Saito, A.; Takeda, T.; Tanuma, A.; Xie, Y.S.; Sato, K.; Kazama, J.J.; Geiyo, F. Evidence indicating that renal tubular metabolism of leptin is mediated by megalin but not by the leptin receptors. Endocrinology 2004, 145, 3935–3940. [CrossRef]

115. Dhanda, D.S.; Frey, W.; Leopold, D.; Kompella, U.B. Approaches for drug deposition in the human olfactory epithelium. Drug Deliv. Technol. 2005, 5, 64–72.

116. Hanson, L.R.; Frey, W.H., 2nd. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008, 9 (Suppl. 3), S5. [CrossRef] [PubMed]

117. National Center for Biotechnology Information. PubChem Patent Summary for WO-9107947-A1. Available online: https://pubchem.ncbi.nlm.nih.gov/patent/WO-9107947-A1 (accessed on 16 April 2022).

118. Ross, T.M.; Martinez, P.M.; Renner, J.C.; Thorne, R.G.; Hanson, L.R.; Frey, W.H. Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: A non-invasive treatment strategy for multiple sclerosis. J. Neuroimmunol. 2004, 151, 66–77. [CrossRef] [PubMed]

119. Thorne, R.G.; Pronk, G.J.; P’Admanabhan, V.; Frey, W.H. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004, 127, 481–496. [CrossRef] [PubMed]

120. De Rosa, R.; Garcia, A.A.; Bracchi, S.; Capsoni, S.; Maffei, L.; Berardi, N.; Cattaneo, A. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc. Natl. Acad. Sci. USA 2005, 102, 3811–3816. [CrossRef]

121. Sheikov, N.; McDannold, N.; Sharma, S.; Hynynen, K. Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium. Ultrasound Med. Biol. 2017, 43, 1093–1104. [CrossRef] [PubMed]

122. Bynoe, M.S.; Viret, C.; Yan, A.; Kim, D.-G. Adenosine receptor signaling: A key to opening the blood-brain door. Front. Neurosci. 2021, 15, 64–72. [CrossRef] [PubMed]

123. Liu, X.F.; Fawcett, J.R.; Hanson, L.R., 2nd. The window of opportunity for treatment of focal cerebral ischemic damage by noninvasive intranasal insulin-like growth factor-I in rats. J. Stroke Cerebrovasc. Dis. Off. J. Natl. Stroke Assoc. 2004, 13, 16–23. [CrossRef]

124. Jin, K.L.; Xie, L.; Childs, J.; Sun, Y.J.; Mao, X.O.; Logvinova, A.; Greenberg, D.A. Cerebral neurogenesis is induced by intranasal administration of growth factors. Ann. Neurol. 2003, 53, 405–409. [CrossRef]

125. Sek, K.; Molck, C.; Stewart, G.D.; Kats, L.; Darcy, P.K.; Beavis, P.A. Targeting Adenosine Receptor Signaling in Cancer Immunotherapy. Int. J. Mol. Sci. 2018, 19, 3837. [CrossRef] [PubMed]

126. Effendi, W.I.; Nagano, T.; Kobayashi, K.; Nishimura, Y. Focusing on Adenosine Receptors as a Potential Targeted Therapy in Human Diseases. Cells 2020, 9, 785. [CrossRef] [PubMed]

127. Ongini, E.; Fredholm, B.B. Pharmacology of adenosine A2A receptors. Trends Pharmacol. Sci. 1996, 17, 364–372. [CrossRef]

128. Fredholm, B.B.; Ijzerman, A.P.; Jacobson, K.A.; Linden, J.; Muller, C.E. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update. Pharmacol. Rev. 2011, 63, 1–34. [CrossRef] [PubMed]

129. Bynoe, M.S.; Viret, C.; Yan, A.; Kim, D.G. Adenosine receptor signaling: A key to opening the blood-brain door. Fluids Barriers CNS 2015, 12, 20. [CrossRef] [PubMed]

130. Ledent, C.; Vagueois, J.M.; Schiffrman, S.N.; Pedrazzini, T.; ElYacoubi, M.; Vanderhaegen, J.J.; Costentin, J.; Heath, J.K.; Vassart, G.; Parmentier, M. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A(2a) receptor. Nature 1997, 388, 674–678. [CrossRef]

131. Zhao, G.; Linke, A.; Xu, X.B.; Ochoa, M.; Belloni, F.; Belardelli, L.; Hintze, T.H. Comparative profile of vasodilation by CVT-3146, a novel A(2A) receptor agonist, and adenosine in conscious dogs. Pharmacol. Rev. 2011, 63, 481–496. [CrossRef] [PubMed]

132. Wala, K.; Szlasa, W.; Saczko, J.; Rudno-Rudzinska, J.; Kulbacka, J. Modulation of Blood-Brain Barrier Permeability by Activating Adenosine A2 Receptors in Oncological Treatment. Biomolecules 2021, 11, 633. [CrossRef]

133. Glaser, F.; Steinberg, D.M.; Vakser, I.A.; Ben-Tal, N. Residue frequencies and pairing preferences at protein-protein interfaces. Proteins 2001, 43, 89–102. [CrossRef]

134. Bobermin, L.D.; Roppa, R.H.A.; Quincozes-Santos, A. Adenosine receptors as a new target for resveratrol-mediated glioprotection. Biochim. Biophys. Acta Mol. Basis Dis. 2016, 1865, 634–67. [CrossRef]

135. Zhang, J.L.; Liu, H.; Du, X.S.; Guo, Y.; Chen, X.; Wang, S.N.; Fang, J.Q.; Cao, P.; Zhang, B.; Liu, Z.; et al. Increasing of Blood-Brain Barrier Permeability through Transcellular and Paracellular Pathways by Microbubble-Enhanced Diagnostic Ultrasound in a C6 Glioma Model. Front. Neurosci. 2017, 11, 86. [CrossRef] [PubMed]

136. Shenkov, N.; McDonnell, N.; Sharma, S.; Hynynen, K. Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium. Ultrasound Med. Biol. 2008, 34, 1093–1104. [CrossRef] [PubMed]

137. Park, J.; Aryal, M.; Vykhodtseva, N.; Zhang, Y.Z.; McDonnell, N. Evaluation of permeability, doxorubicin delivery, and drug retention in a rat brain tumor model after ultrasound-induced blood-tumor barrier disruption. J. Control. Release 2017, 250, 77–85. [CrossRef] [PubMed]

138. Aryal, M.; Fischer, K.; Gentile, C.; Gitto, S.; Zhang, Y.Z.; McDonnell, N. Effects on P-Glycoprotein Expression after Blood-Brain Barrier Disruption Using Focused Ultrasound and Microbubbles. PLoS ONE 2017, 12, e0166061. [CrossRef]

139. McMahon, D.; Oakden, W.; Hynynen, K. Investigating the effects of dexamethasone on blood-brain barrier permeability and inflammatory response following focused ultrasound and microbubble exposure. Theranostics 2020, 10, 1604–1618. [CrossRef]
140. Samiotaki, G.; Karakatsani, M.E.; Buch, A.; Papadopoulos, S.; Wu, S.Y.; Jambawalikar, S.; Konofagou, E.E. Pharmacokinetic analysis and drug delivery efficiency of the focused ultrasound-induced blood-brain barrier opening in non-human primates. *Magn. Reson. Imaging* 2017, 37, 273–281. [CrossRef]

141. Dasgupta, A.; Liu, M.; Ojha, T.; Storm, G.; Kießling, F.; Lammers, T. Ultrasound-mediated drug delivery to the brain: Principles, progress and prospects. *Drug Discov. Today. Technol.* 2016, 20, 41–48. [CrossRef]

142. Xu, X.; Wei-Adrian, D.; Silburt, J. Glutamate Induces Blood-Brain Barrier Permeability through Activation of N-Methyl-D-Aspartate Receptors. *J. Neurosci.* 2016, 36, 12296–12298. [CrossRef]

143. Beisteiner, R.; Matt, E.; Fan, C.; Baldysiaik, H.; Schonfeld, M.; Novak, T.P.; Amini, A.; Aslan, T.; Reinecke, R.; Lehrner, J.; et al. Transcranial Pulse Stimulation with Ultrasound in Alzheimer’s Disease—A New Navigated Focal Brain Therapy. *Adv. Sci.* 2020, 7, 1902583. [CrossRef]

144. Meng, Y.; Pople, C.B.; Lea-Banks, H.; Abrahao, A.; Davidson, B.; Suppiah, S.; Vecchio, L.M.; Samuel, N.; Mahmud, F.; Hynynen, K.; et al. Safety and efficacy of focused ultrasound induced blood-brain barrier opening, an integrative review of animal and human studies. *J. Control. Release* 2019, 309, 25–36. [CrossRef]

145. Villringer, K.; Cuesta, B.E.S.; Ostwaldt, A.C.; Grittner, U.; Brunecker, P.; Khalil, A.A.; Schindler, K.; Eisenblatter, O.; Audebert, H.; Fiebach, J.B. DCE-MRI blood-brain barrier assessment in acute ischemic stroke. *Neurology* 2017, 88, 433–440. [CrossRef] [PubMed]

146. Yang, J.; Li, Q.; Wang, Z.Y.; Qi, C.F.; Han, X.N.; Lan, X.; Wan, J.R.; Wang, W.Z.; Zhao, X.C.; Hou, Z.P.; et al. Multimodality MRI assessment of grey and white matter injury and blood-brain barrier disruption after intracerebral haemorrhage in mice. *Sci. Rep.* 2017, 7, 40385. [CrossRef] [PubMed]

147. Shiraishi, K.; Kawano, K.; Minowa, T.; Maitani, Y.; Yokoyama, M. Preparation and in vivo imaging of PEG-poly(L-lysine)-based polymeric micelle MRI contrast agents. *J. Control. Release* 2009, 136, 14–20. [CrossRef] [PubMed]

148. Posadas, I.; Monteagudo, S.; Céha, V. Nanoparticles for brain-specific drug and genetic material delivery, imaging and diagnosis. *Nanomed. Lond. Engl.* 2016, 11, 833–849. [CrossRef]

149. Ramanathan, S.; Archunan, G.; Sivakumar, M.; Selvan, S.T.; Fred, A.L.; Kumar, S.; Gulyas, B.; Padmanabhan, P. Theranostic applications of nanoparticles in neurodegenerative disorders. *Int. J. Nanomed.* 2018, 13, 5561–5576. [CrossRef]

150. Teleanu, D.M.; Chircov, C.; Grumezescu, A.M.; Volceanov, A.; Teleanu, R.I. Contrast Agents Delivery: An Up-to-Date Review of Nanodiagnostics in Neuroimaging. *Nanomaterials* 2019, 9, 542. [CrossRef]

151. Richard, S.; Saric, A.; Boucher, M.; Slomianny, C.; Gefroy, F.; Mériaux, S.; Lalatonne, Y.; Petit, P.X.; Motte, L. Antioxidative Theranostic Iron Oxide Nanoparticles toward Brain Tumors Imaging and ROS Production. *ACS Chem. Biol.* 2016, 11, 2812–2819. [CrossRef]

152. Richard, S.; Boucher, M.; Lalatonne, Y.; Mériaux, S.; Motte, L. Iron oxide nanoparticle surface decorated with cRGD peptides for magnetic resonance imaging of brain tumors. *Biochim. Biophys. Acta Gen. Subj.* 2017, 1861, 1515–1520. [CrossRef]

153. Meola, A.; Rao, J.H.; Chaudhary, N.; Sharma, M.; Chang, S.D. Gold Nanoparticles for Brain tumor imaging: A Systematic Review. *Front. Neurol.* 2018, 9, 328. [CrossRef]

154. Mahan, M.M.; Doiron, A.L. Gold Nanoparticles as X-Ray, CT, and Multimodal Imaging Contrast Agents: Formulation, Targeting, and Methodology. *J. Nanomater.* 2018, 2018, 5837276. [CrossRef]

155. Cho, J.H.; Kim, A.R.; Kim, S.H.; Lee, S.J.; Chung, H.; Yoon, M.Y. Development of a novel imaging agent using peptide-coated gold nanoparticles toward brain glioma stem cell marker CD133. *Acta Biomater.* 2017, 47, 182–192. [CrossRef] [PubMed]

156. Rammohan, N.; Holbrook, R.J.; Rotz, M.W.; MacRenaris, K.W.; Preslar, A.T.; Carney, C.E.; Reichova, V.; Meade, T.J. Gd(III)-Gold Nanoclusters Provide Remarkable Cell Labeling for High Field Magnetic Resonance Imaging. *Bioconjugate Chem.* 2016, 28, 153–160. [CrossRef]

157. Azria, D.; Blanquer, S.; Verdier, J.M.; Belami, E. Nanoparticles as contrast agents for brain nuclear magnetic resonance imaging in Alzheimer’s disease diagnosis. *J. Mater. Chem. B* 2017, 5, 7216–7237. [CrossRef] [PubMed]

158. Gale, E.M.; Caravan, P. Gadolinium-Free Contrast Agents for Magnetic Resonance Imaging of the Central Nervous System. *Acs Chem. Neurosci.* 2018, 9, 395–397. [CrossRef] [PubMed]

159. Cai, X.X.; Zhu, Q.X.; Zeng, Y.; Zeng, Q.; Chen, X.L.; Zhan, Y.H. Manganese Oxide Nanoparticles as MRI Contrast Agents in Tumor Multimodal Imaging and Therapy. *Int. J. Nanomed.* 2019, 14, 8321–8344. [CrossRef] [PubMed]

160. Vieira, D.B.; Gamarra, L.F. Getting into the brain: Liposome-based strategies for effective drug delivery across the blood-brain barrier. *Int. J. Nanomed.* 2016, 11, 5381–5414. [CrossRef]

161. Bulbake, U.; Doppalapudi, S.; Kommieni, N.; Khan, W. Liposomal Formulations in Clinical Use: An Updated Review. *Pharmaceutics* 2017, 9, 12. [CrossRef]

162. Pattini, B.S.; Chapin, V.V.; Torchilin, V.P. New Developments in Liposomal Drug Delivery. *Chem. Rev.* 2015, 115, 10938–10966. [CrossRef]

163. Loyse, A.; Thangaraj, H.; Easterbrook, P.; Ford, N.; Roy, M.; Chiller, T.; Govender, N.; Harrison, T.S.; Bicanic, T. Cryptococcal meningitis: Improving access to essential antifungal medicines in resource-poor countries. *Lancet Infect. Dis.* 2013, 13, 629–637. [CrossRef]

164. Benesch, M.; Urban, C. Liposomal cytarabine for leukemic and lymphomatous meningitis: Recent developments. *Expert Opin. Pharmacother.* 2008, 9, 301–309. [CrossRef]
191. Van Norman, G.A. Limitations of Animal Studies for Predicting Toxicity in Clinical Trials Is it Time to Rethink Our Current Approach? Jacc Basic Transl. Sci. 2019, 4, 845–854. [CrossRef] [PubMed]
192. GlobalDataHealthcare. Central Nervous System Resumed Trials Showed Biggest Increase in 2021. Available online: https://www.clinicaltrialsarena.com/comment/central-nervous-system-resumed-trials (accessed on 5 April 2022).